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a b s t r a c t
Modern antiretroviral therapies have provided HIV-1 infected patients longer lifespans and better quality
of life. However, several neurological complications are now being seen in these patients due to HIV-1
associated injury of neurons by infected microglia and astrocytes. In addition, these effects can be further
exacerbated with opiate use and abuse. One possible mechanism for such potentiation effects of opiates
is the interaction of the mu opioid receptor (MOR) with the chemokine receptor CCR5 (CCR5), a known
HIV-1 co-receptor, to formMOR–CCR5 heterodimer. In an attempt to understand this putative interaction
and its relevance to neuroAIDS, we designed and synthesized a series of bivalent ligands targeting the
putative CCR5–MOR heterodimer. To understand how these bivalent ligands may interact with the het-
erodimer, biological studies including calcium mobilization inhibition, binding affinity, HIV-1 invasion,
and cell fusion assays were applied. In particular, HIV-1 infection assays using human peripheral blood
mononuclear cells, macrophages, and astrocytes revealed a notable synergy in activity for one particular
bivalent ligand. Further, a molecular model of the putative CCR5–MOR heterodimer was constructed,
docked with the bivalent ligand, and molecular dynamics simulations of the complex was performed
in a membrane-water system to help understand the biological observation.
Published by Elsevier Ltd.
1. Introduction
The progression of human immunodeficiency virus (HIV)-1/
acquired immunodeficiency syndrome (AIDS) has been shown to
be accelerated by abused substances such as opioids, cocaine,
and alcohol.1–5 While both abusive and addictive behavior of
opioids are mainly associated with the mu opioid receptor
(MOR), opioids can also negatively impact the immune system
via immunomodulation regulated through the MOR.5,6 These dele-
terious results on the immune system may affect the progression
of HIV/AIDS.7
The major co-receptor that regulates the invasion of monotro-
pic (or R5-tropic) HIV-1 is the chemokine receptor CCR5, which
is expressed in immune and non-immune cells.8–11 In 2007, mar-
aviroc, a CCR5 antagonist, was approved by the FDA. In combina-
tion with other antiretroviral therapies (ART), maraviroc has
improved the overall health of HIV-1 infected indidivuals.12
However, despite the use of ART and reductions in plasma viral
loads to near undetectable levels, there remain significant CNS
complications. In particular, HIV-associated neurocognitive disor-
ders (HAND) are evident in nearly half of AIDS patients and lead
to abnormalities in neurocognition, behavior, and motor control.13
The neurological complications of neuro-acquired immunodefi-
ciency syndrome (neuroAIDS) are largely due to the injury of neu-
rons caused by inflammation and the release of viral products from
infected microglia and astrocytes.14
The progression of neuroAIDS has been linked to opioid abuse
and addiction. A key site of HIV and opioid convergence may be
caused by interactions between the CCR5 and the MOR.4,6,15–18
For example, MOR agonists can upregulate the expression of
CCR5 and promote HIV-1 infection, while MOR antagonists may
block these effects.19 Opioids can also exacerbate the amount of
indirect neuronal injury in neurons and glia through HIV-1 induced
CNS inflammation.15,17 There is additional evidence that the speci-
fic opioid-dependent neuronal injury may be primarily induced by
MOR expressing glia in the CNS.6
http://dx.doi.org/10.1016/j.bmc.2016.09.059
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Moreover, the MOR and the CCR5 have been shown to
heterodimerize with each other and undergo crosstalk.20–22 This
interaction affects immune cell function and may produce the syn-
ergistic effects of HIV and opioid drug co-exposure seen in neu-
roAIDS progression.19,21 Recently, a bivalent compound
containing both a MOR and a CCR5 antagonist pharmacophore
was designed and synthesized in our lab in an attempt to study
the pharmacological implication of MOR–CCR5 heterodimerization
in neuroAIDS (Fig. 1).23–25 This new ligand (compound 1b) showed
higher potency in antiviral activity in human astrocytes than mar-
aviroc or a mixture of naltrexone (a MOR antagonist) and maravi-
roc. Presumably, by targeting the putative MOR–CCR5
heterodimer, the bivalent ligand was able to block viral invasion
more effectively.25 More significantly, when morphine was pre-
sent, the inhibition of infectivity by maraviroc was abolished in
astrocytes, but the bivalent ligand retained its antiviral activity
under the same conditions.25 To understand the pharmacological
profile and structure–activity relationship (SAR) of this bivalent
ligand, we further designed and studied several analogues of com-
pound 1b along with their monovalent control compounds. Herein,
we report the SAR study of this series of bivalent compounds as
chemical probes targeting the putative MOR–CCR5 heterodimer
through binding assays, functional assays, HIV-1 infection assays,
and molecular modeling simulations.
2. Results and discussion
2.1. Compound design and synthesis
It has been postulated that the linker length between the two
pharmacophores of bivalent ligands is critical for their activity
and may serve as an indicator for the distance between the two
binding pockets of a GPCR dimer.26 The first bivalent ligand (desig-
nated as compound 1b, Fig. 1) was designed with an overall length
of 21 atoms based upon previous bivalent ligand reports involving
the MOR,23 along with two control compounds with the same
length of spacer (compound 2b for monovalent control attaching
maraviroc, compound 3b for monovalent control attaching nal-
trexone). In order to study how linker length affects activity, the
overall length was decreased or increased by two atoms in com-
pounds 1a or 1c respectively. Concurrently, four new monovalent
control compounds were synthesized with either a 19 atom linker
(2a and 3a) or a 23 atom linker (2c and 3c) for both maraviroc and
naltrexone pharmacophores.
To study linker attachment position influence, another ligand
(1d) was designed by switching the linker attachment position
from the 40-position (para, as in 1b) of phenyl ring in maraviroc
to its 30-position (meta). The corresponding control compound 3d
was then prepared.
Figure 1. Chemical structures of naltrexone, maraviroc, bivalent ligands (1a–d), and monovalent ligands (2a–c), and 3a–d).
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The synthetic route for 30-amino maraviroc precursor (5) that
was needed to prepare ligand 1d is shown in Scheme 1. 3-Bro-
mocinnamic acid was first protected via an esterification reaction
using isopropanol (i-PrOH) and a catalytic amount of H2SO4 while
being refluxed. The overall yield of 6 was 79%. The bromide was
then converted to the amine (7) using lithium hexamethyldisi-
lazide (LHMDS), Pd2(dba)3, and P(t-Bu)3 with yields ranging from
50% to 70%. Immediately after purification, the amine of 7was pro-
tected with a Boc group using di-tert-butyl dicarbonate stirred in a
1:1 mixture of H2O/dioxane with NaHCO3 at room temperature
which gave 8 at yields up to 76%. The stereoselective Michael
addition to form 9 was achieved by using lithium (R)-(+)-N-
benzyl-a-methylbenzylamide. This reaction has been used
previously in multiple synthetic routes to selectively form enan-
tiomerically pure adducts.23,27–29 Both column chromatography
and recrystallization were used to purify the product with yields
up to 50%. Saponification of the isopropyl ester (9) to form the
carboxylic acid 10 was accomplished by refluxing in MeOH/H2O
with LiOH. After reaction workup, a yield of 88% was achieved.
Next, an amide coupling between 10 and 11 to form 12 was
done by using EDCI with a yield of 74%. The reduction of the
(R)-(+)-N-benzyl-a-methylbenzylamide to form the amine 13
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Scheme 2. Synthetic route of bivalent ligands (1a, 1b, 1c, and 1d). (a) CbzCl, DCM, MeOH, 5 C, 60%; (b) THF, diglycolic anhydride, rt, 64%; (c) EDCI, HOBt, TEA, 42HCl, 4 Å MS,
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proved to be more difficult compared to the same reaction for the
4-amino maraviroc derivative.23 The hydrogenation of 12 was first
attempted using 10% Pd/C and 60 psi H2 in MeOH, but very little
product was formed even after 7 days. Therefore, new conditions
were tried using 10% Pd/C, 60 psi H2, and 2 equiv of AcOH in MeOH.
A yield of 91% for 13was achieved. Therefore, acid was essential for
facilitating the reduction of 12 to 13. Reduction of the amide, 13, to
form 14 was accomplished by using lithium aluminum hydride.
Another EDCI mediated amide coupling was performed between
14 and 15 to form 16. The 4,4-difluorocyclohexanecarboxylic acid
(15) had previously been synthesized from ethyl-4-oxocyclohex-
anecarboxylate.23,30 The Boc-deprotection of 16 was accomplished
using 10% trifluoroacetic acid to afford 5 quantitatively.
The synthesis of compound 1d (Scheme 2) was facilitated by
coupling 5 with 21 using EDCI with a final yield of 26%. The syn-
thetic route for 40-amino maraviroc precursor has been reported
and the chemical synthesis for all the bivalent compounds is
depicted in Scheme 2 and it was similar to the one reported
previously.24
The monovalent control compounds 2a, 3a, 2c, and 3c were
synthesized in the same manner as previously described (Schemes
3 and 4).23 The 30-amino maraviroc monovalent control compound,
3d, was synthesized using the synthetic route in Scheme 4. The
monoprotected diamine 17 was coupled with methylcarbamoyl-
methoxy-acetic acid (22) to form 23. Next, 23 was deprotected
using Pd/C mediated hydrogenation (24) and a diglycolic anhy-
dride group was then added to bring the total linker length to 21
atoms (25). Finally, 25 and 5 were coupled using EDCI to form
the monovalent compound 3d (33% yield).
2.2. Biological evaluation
2.2.1. MOR calciummobilization assays and radioligand binding
assays
The compounds were first subjected to their agonism and
antagonism property tests in the MOR monocloned CHO cells.
The results from MOR calcium mobilization and competitive bind-
ing assays indicated that all the compounds maintained their
recognition to the receptor MOR (Table 1), which supported our
original molecular design pertaining to the MOR part. Compared
to the parent pharmacophore naltrexone, all of the bivalent
compounds showed relatively higher IC50 values for both calcium
mobilization antagonism and receptor binding affinity, while the
linker length did not drastically affect the bivalent compounds’
affinity on the MOR. The 30-position bivalent compound, 1d,
showed the highest Ki value for MOR, but conversely had the low-
est IC50 values for the calcium reflux functional activities, indicat-
ing that the linkage position on the CCR5 pharmacophore did not
influence the recognition on the MOR, which seemed to be reason-
able. Furthermore, the monovalent control compounds, compared
to the corresponding bivalent compounds, did not show any signif-
icant difference regarding their affinity and function on the recep-
tor, which indicated that the linkers were well tolerated in the
recognition of the MOR.
2.2.2. CCR5 calcium mobilization assays and radioligand
binding assays
Compounds were then tested for both their agonism and antag-
onism for the CCR5 in the MOLT-4 cells. We intended to use the
calcium mobilization assay as the preliminary screening tool for
its high throughput property and much lower cost. Prior to use,
CCR5-MOLT-4 cells were transiently transfected with a chimeric
G protein, Gqi5, in order to boost their calcium signaling levels.31
Over a range of concentrations, compounds showed no apparent
agonism of the CCR5 (data not shown).
The CCR5 antagonism assay was then tested through the
inhibition of RANTES (CCL5) stimulated calcium mobilization
and indicated that modification of maraviroc at its phenyl ring
was not very well tolerated (Table 2). The bivalent ligands
1a–d all showed significantly lower potency compared to mar-
aviroc, the parent pharmacophore, which was consistent with
previously described data for similar modifications on the com-
pound.24 In particular, bivalent compound 1b with the 21 atom
linker showed a 60-fold decrease of antagonist potency as com-
pared to maraviroc.23 The decrease in CCR5 antagonism was not
improved by either increasing or decreasing linker length as
seen for bivalent compounds 1c or 1a. As a matter of fact, the
optimal linker length for CCR5 antagonism was still 21 atoms.
However, the linker lengths of the monovalent control com-
pounds 3a, 3b, and 3c were directly correlated to their CCR5
antagonism: increasing linker length led to an increase of
CCR5 antagonism.
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When the linker attachment on maraviroc was switched from
the 40- to 30-position of the phenyl ring, a significant difference in
CCR5 antagonism was observed, that was, ligand 1b was ten times
more potent than 1d as a CCR5 antagonist. Therefore, for the biva-
lent compounds, a 40-position attachment was more favored over
the 30-position attachment.
To further verify the direct binding affinity of compound 1b, it
was submitted for radioligand binding affinity study at the CCR5
along with the parent pharmacophore, maraviroc, and its monova-
lent control (compound 3b) at EMD Millipore, a division of Merck
KGaA, Darmstadt, Germany. Apparently introduction of a spacer at
the phenyl ring of maraviroc did dramatically influence the recog-
nition to the receptor CCR5. It was decided not to apply such test
for other less potent compounds.
2.2.3. HIV-1 p24 production in PMBC and macrophage cultures
PBMCs, macrophages, and microglia expressing CCR5 are
preferentially susceptible to infection by R5-tropic strains of
HIV.32–36 Accordingly, the use of PBMCs and macrophages is highly
appropriate for testing the effects of these bivalent ligands on
blocking infection by R5-tropic strains of HIV.
Viral production in HIV-infected PBMCs was assessed by mea-
suring p24 levels following 5 days of exposure to maraviroc and/
or the bivalent ligands (Fig. 2A). Overall, there was a significant
effect of the treatments on viral production in PBMCs (p < 0.005;
ANOVA). As anticipated, exposure to 500 nM maraviroc (MVC) sig-
nificantly decreased viral production (p < 0.00025 vs. HIV-1 infec-
tion alone; Dunnett’s test, two-tailed). Exposure to bivalent
ligand 1b also significantly reduced p24 levels in PBMCs. Interest-
ingly, viral levels were reduced following exposure to all three con-
centrations of bivalent ligand 1b (p <0.02; Dunnett’s test) without
apparent concentration response effect. Bivalent ligand 1c mark-
edly reduced p24 levels only at the highest concentration (1 lM)
(p <0.05; Dunnett’s test), while bivalent ligand 1a did not signifi-
cantly reduce viral production in PBMC cultures at any of the con-
centrations tested.
Not unexpectedly, the bivalent ligands that inhibited HIV-1 pro-
duction in PBMCs also reduced p24 levels in macrophages resulting
in a significant overall treatment effect in macrophages
(p <0.00025; ANOVA) (Fig. 2B). Maraviroc alone (MVC) significantly
restricted viral production (p <0.00005 vs. HIV-1 infection alone;
Dunnett’s test, two-tailed). Exposure to bivalent ligands 1b and
1c significantly reduced p24 levels in macrophages, but only at
the highest 1 lM concentration (p <0.005 and p <0.025, respec-
tively; Dunnett’s test). Similar to the findings in PBMCs, bivalent
ligand 1a failed to diminish p24 levels in macrophages even at
the highest 1 lM concentration.
2.2.4. HIV-1 p24 production in astrocyte cultures
Primary human astrocytes were chosen because they are a
major cellular site of infection in the CNS and are a key cellular site
where opioids act to potentiate the pathophysiological effects of
HIV-1 infection.5,6,16,18,25,37–39 Concentration response effects of
viral infection inhibition were observed for all three bivalent com-
pounds (Fig. 2C). By virtue of the fact that astrocytes display lower
rates of HIV-1 infectivity than PBMCs or macrophages and because
of reduced rates of relative infectivity using the p24 assay in the
present study, we additionally assayed infectivity by examining
HIV-1 Tat expression in astrocytes.40–43
2.2.5. HIV-1 Tat expression in astrocytes
Among three bivalent compounds, compound 1b was picked to
be evaluated in this assay because of its favorable binding affinities
at both receptors as well as its more significant effect in all three
HIV-1 p24 production assay results. Figure 3 shows the effect that
1b and maraviroc have on the infection of astrocytes by HIV-1 with
and without the presence of morphine stimulation. Relative
expression of Tat was significantly increased in astrocytes after
Table 1
MOR Ca2+ inhibition and [3H]NLX competitive binding assays results.a
Compd n Linkage Ca2+ assay IC50 (nM) [3H]NLX binding Ki (nM)
NTX NA NA 2.87 ± 0.27 0.39 ± 0.04
1a 3 40 21.8 ± 5.6 3.80 ± 0.55
2a 3 NA 92.1 ± 20.1 0.78 ± 0.12
1b 5 40 40.0 ± 4.8b 3.24 ± 0.34
2bb 5 NA 37.8 ± 4.4 9.2 ± 3.4
1c 7 40 21.9 ± 3.7 6.49 ± 0.16
2c 7 NA 41.4 ± 24.6 1.11 ± 0.08
1d 5 30 17.1 ± 4.9 10.0 ± 0.6
a The values are the means ± SEM of at least three independent experiments. Ca2+ mobilization assay was performed on hMOR-CHO cells. Membranes for radioligand
binding assays were prepared from mMOR-CHO cells. NLX, Naloxone. NA, not applicable.
b Data taken from Ref. 24.
Table 2
CCR5 Ca2+ mobilization and [125I]MIP-1a competitive binding assays results.a
Compd n Linkage Ca2+ assay IC50 (nM) Radioligand bindingb Ki (nM)
Maraviroc — — 2.1 ± 0.4 0.24 ± 0.06
1a 3 40 2413 ± 617 ND
3a 3 40 948 ± 34 ND
1bb 5 40 126 ± 28 239 ± 56
3bb 5 40 622 ± 36 151 ± 44
1c 7 40 543 ± 79 ND
3c 7 40 392 ± 51 ND
1d 5 30 1340 ± 110 ND
3d 5 30 129 ± 42 ND
a The values are the means ± SEM of at least three independent experiments. Membranes for radioligand binding assay were prepared from mMOR-CHO cells. Ca2+
mobilization assay was performed on MOLT4-CCR5 cells. NA, not applicable. ND, not determined.
b Data taken from Ref. 24.
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infection with R5 HIV-1SF162 alone or in combination with mor-
phine (M). As expected, exposure to maraviroc (MVC) significantly
decreased viral entry, while co-exposure with morphine com-
pletely abolished the antiviral effect of maraviroc causing a <4-fold
increase in Tat expression in astrocytes. The addition of the biva-
lent ligand 1 was extremely effective in inhibiting viral entry in
astrocytes, causing a 3.3-fold decrease in viral entry when com-
pared to maraviroc alone and a 7-fold decrease when compared
to MVC + NTX. Co-exposure with morphine had no significant
effect on the viral inhibition effect of the bivalent ligand 1b. The
results showed that morphine impairs the antiviral function of
maraviroc in human astrocytes while the bivalent ligand 1b can
function as a potent inhibitory entity in astrocytes even under
exposure from morphine interactions. These results supported
our hypothesis that a properly designed bivalent ligand may syner-
gistically block the HIV-1 invasion to host cells.
2.2.6. Cell fusion assays
While the calcium mobilization assays can measure the activity
of the compounds at the receptor level, it does not show the anti-
HIV invasion activity of the compounds. Cell fusion assays are an
alternative to working with live virus and have been shown to
mimic the HIV invasion process.44 Figure 4 illustrates the general
process for the cell fusion assay in which two cell populations,
called the target and effector cells, are used. Fundamentally, the
target cells act as the host cells that are infected by HIV and the
effector cells act as the virus. A CCR5–MOR CHO cell line was used
as the basis for the target cells and was transiently transfected with
CD4 and a luciferase reporter. Human embryonic kidney (HEK)
cells were used as the effector cells and were transiently trans-
fected with HIV-1 gp120 and T7 polymerase. Once overlaid, CD4
and gp120 form a complex and interact with the CCR5–MOR het-
erodimer and initiate the fusion process. Upon cell fusion, the luci-
ferase gene reporter is transcribed, and after 18 h luminescence is
measured. Adding a CCR5 antagonist, such as maraviroc, during the
overlay process inhibits the fusion process and leads to a decrease
in luminescence. Therefore, addition of the bivalent compounds
should also inhibit the fusion process.
Figure 5 is the results from a cell fusion assay with and without
morphine stimulation during the fusion process. Upon the addition
of morphine and +CD4 to effector cells, there was a significant
increase (p <0.05) in fusion compared to the +CD4 effector cells
alone. Addition of maraviroc significantly lowered cell fusion,
while surprisingly; addition of morphine did not influence the cell
fusion inhibition effect of maraviroc. On the other hand, the inhibi-
tory effect of 1b alone on the cell fusion was not as significant as
maraviroc alone while its inhibitory effect was amplified by 2-fold
when morphine was present. These results were partially agree-
able with what was observed in the virus invasion assay consisting
Figure 2. Preliminary screening results of HIV-1 p24 production in PMBC,
macrophage, and astrocyte cultures. PMBC, macrophage, and astrocyte cultures
were exposed to R5-tropic HIV virus and varying concentrations of compounds 1a–
c. Inhibition of p24 production was measured using ELISA and compared to the
control (maraviroc).
Figure 3. HIV-1 invasion assay in human astrocytes. HIV-1SF162 infectivity in
human glia was determined based on the relative amount of Tat protein expressed
by the virus using a luciferase based assay. HA: human astrocytes, uninfected cells;
R5: R5-tropic HIV-1; M: morphine; MVC: maraviroc; NTX: naltrexone; BIVALENT:
compound 1b. Values are absorbance ± SEM of 3 independent experiments at 18 h
post-infection (*p <0.005 vs. un-infected cells; $p <0.05 vs. R5 HIV-1; #p <0.05 vs. M;
–p <0.05 vs. MVC; §p <0.05 vs. M + MVC; ^p <0.05 vs. MVC + NTX; ^^p <0.05 vs. M
+ MVC + NTX; Xp <0.05 vs. bivalent).
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of astrocytes and HIV-1 in a native system that the bivalent ligand
1b showed more significant inhibitory effect upon the addition of
morphine than without morphine.
2.2.7. mRNA levels of CCR5 and MOR
To understand the disconnection between the cell fusion assay
results and the astrocyte HIV-1 invasion assay results, we tried to
find out the relative protein expression levels in the cells between
the two assays. Using RT-PCR, the mRNA expression levels of CCR5
and MOR were analyzed for both astrocytes and the CCR5–MOR
CHO cells (Fig. 6). From two batches of primary human astrocytes
we adopted in the assays, the CCR5 mRNA level was about 11-fold
higher than the MOR while in the CCR5–MOR CHO cell line the
mRNA level of the CCR5 was at least 24-fold higher than the
MOR. That is, there was at least 2-fold difference in the ratio of
MOR and CCR5 between the two cell lines with the CCR5–MOR
CHO cell line having a much higher expression of the CCR5 than
the MOR. Therefore we postulated that with much higher amounts
of CCR5 than MOR, there would be a lower level of formation of
CCR5–MOR heterodimers in the CCR5–MOR CHO cell line than in
the astrocytes. Since the bivalent compounds would preferentially
bind to the putative CCR5–MOR heterodimers, fewer available het-
erodimers for bivalent ligand binding in the CCR5–MOR CHO cells
than in the astrocytes would lead to less significant inhibitory
effect of the ligand.
2.3. Molecular modeling studies
To understand potential interaction of the ligand 1b with the
putative receptor dimers, as well as its relatively low affinity to
the CCR5 receptor, we adopted computational modeling to explore
the relationship between the CCR5–MOR heterodimer and bivalent
compound 1b. Several methods have been used to model GPCR
homodimers and heterodimers. Until recently, the most prominent
way to model dimerization was to use protein–protein docking
programs such as ZDOCK, GRAMM, or Rosetta.45 Recently, several
GPCR homodimer crystal structures have been characterized and
offered a new route to model GPCR dimerization.46–48 These struc-
tures have either a TM4–TM5 or a TM5–TM6 interface, which both
Figure 4. Cell fusion assay scheme adopted to mimic HIV invasion without live
virus.
Figure 5. Cell fusion assay based upon luminescence from expressed luciferase
reporter gene. For morphine stimulation, 300 nM morphine was added. 100 nM
maraviroc, and 3000 nM 1b were used. Values are representative of 4 assays run.
(*p <0.001 vs. +CD4 + morphine; $p <0.05 vs. +CD4 + morphine; #p <0.01 vs. +CD4
+ morphine.) This trend was seen in an additional three assays.
Figure 6. mRNA levels of MOR and CCR5 in the CCR5–MOR CHO cell line and in
primary human astrocytes.25
C. K. Arnatt et al. / Bioorg. Med. Chem. 24 (2016) 5969–5987 5975
represent feasible GPCR dimer model.45,47,49 Current knowledge
also suggests that GPCRs do not undergo significant conforma-
tional changes upon dimerization.45 Therefore, GPCR dimers can
now be modeled by using the experimentally observed dimers
and overlaying the receptors being studied onto it and aligning
them based upon sequence homology. This technique has been
successfully applied to model 5-HT1A homodimers and has been
experimentally verified.49
Upon the time of our initial molecular design effort, neither the
crystal structure of the MOR or the CCR5 was available for struc-
ture-based design. Thus compound 1b and its analogues were
designed based on the homology models of the CCR5 and the
MOR from our own efforts.50,51 Later on the crystal structure of
the MOR homodimer was made available47 and then adopted by
us as the template for the CCR5–MOR heterodimer. Their heterodi-
mer interface was assumed to be between TM5 and TM6. For the
CCR5 counterpart, we had to adopt the then available CXCR4 crys-
tal structure48 as a template to rebuild our CCR5 homology model
in order to construct the heterodimer model, as elaborated below.
More recently the crystal structures of the CCR5 and its dimers
were reported,52 thus, providing a meaningful comparison for our
future exploration.
In detail, first, a CCR5 homology model was constructed using
the CXCR4 crystal structure as the template structure.48 Second,
one MOR receptor in the MOR dimer crystal structure was kept
in place while the other was overlaid with the CCR5 homology
model, aligned based upon their homology, and replaced. Before
ligand docking, preliminary heterodimer model refinement was
carried out through energy minimization using the MMFF94 force
field. An alternative way to build this dimer model would be to
construct CCR5 homology model based on one of the MOR mono-
mers in its homodimer structure. Though it would provide a more
conserved heterodimer model, the lower homology between the
MOR and the CCR5 compared to that between the CXCR4 and the
CCR5 could be an intrinsic shortcoming, and therefore was not
adopted for this method.
Docking compound 1b into both binding pockets of the hetero-
dimer model simultaneously proved to be difficult. Therefore, a
new method had to be devised so that the two different portions
of the bivalent compound could be docked individually, in their
respective receptor, and then connected to each other with the
(19-atom) linker. Since the MOR homodimer was co-crystalized
with its irreversible antagonist b-FNA,47 the naltrexone portion of
the bivalent compound was well aligned with the morphinan
structure of b-FNA.47 Once aligned, the 6-b position of the naltrex-
one portion points upward toward the TM-5/TM-6 heterodimer
interface, which provided an appropriate orientation to allow for
the linker to connect to maraviroc and reach for the CCR5 binding
pocket, with the assumed TM5/TM6 heterodimer interface.
Next maraviroc was docked into the CCR5 portion of the hetero-
dimer using GOLD.53 The docking poses subsequently obtained
were manually evaluated to select those that allow geometrically
reasonable attachment between the phenyl group of maraviroc
and the linker portion of 1b near the TM5 and TM6 heterodimer
interface. Of those poses, the one with the highest GOLD docking
score was used. After attaching maraviroc to the 19-stom linker
portion of compound 1b, the system was energy minimized.
Molecular dynamics, NAMD, was then used to interpret the sta-
bility of the heterodimer-bivalent compound complex.54 Several
steps were taken in order to prepare the heterodimer–ligand com-
plex for dynamics simulation: the complex was first added to a
lipid bilayer and then solvated with a pre-defined water box with
appropriate types and concentrations of ions to accurately simu-
late its native membrane environment (Fig. 7).49,55,56 Altogether,
the dimer–ligand–lipid–water–ion system had 162,385 atoms. A
series of minimizations was then done in a step-wise manner to
slowly equilibrate and energy minimize the components of the
complex. After 10 ns of dynamics simulation the system was equi-
librated as indicated by the RMSD (Fig. S1, Supporting information)
and total energy (Fig. S2, Supporting information) of the system. A
longer period of simulation (another 10 ns) did not change the out-
come significantly and therefore, was not included in the
discussion.
During the 10 ns of dynamics simulation, the maraviroc portion
of compound 1b partially dislodged from the CCR5 binding pocket,
whereas the naltrexone portion maintained its binding pose lar-
gely within the MOR binding pocket observed in the MOR crystal
structure (Fig. 8).47 This result indicated that for the heterodimer
model, the initial binding mode for compound 1b in CCR5 was
not energetically favored. However, it is also important to note that
only the triazole moiety of maraviroc moved out of the original
CCR5 binding pocket. Figure 8 illustrates that after 6.0 ns of
dynamic simulation the triazole ring rotated upward out of its ini-
tial binding pocket. This shift upward was reflected in the changes
in the RMSD of 1b (Fig. S3, Supporting information). Such an obser-
vation actually was partially in agreement with the later available
maraviroc bound CCR5 crystal structure.52
The change in interactions between compound 1b and the
CCR5–MOR heterodimer at 0 ns and at 6.0 ns was shown in Table 3.
The opioid portion of 1b retained the majority of its interactions
with the MOR binding pocket from its initial binding pose. This
binding pose matched well with that of b-FNA within the MOR
crystal structure.28 However, there were significant changes in
the CCR5 interactions of 1b between these two time points
(Fig. 9). After an additional 4 ns of stimulation, i.e., until the end
of the simulation, 1bmaintained the binding pocket pose observed
at 6.0 ns. These results helped explain the lower CCR5 binding
affinity of the bivalent compound as compared to maraviroc.
The dynamics simulation study could also help explain the
changes in functional activities observed between maraviroc and
1b. As suggested by the simulations, addition of the linker to the
p-phenyl portion of maraviroc led to 1b being able to adopt only
Figure 7. Molecular simulation system for the CCR5–MOR heterodimer in a
membrane (gray), and water box (red) system. The green protein represents the
MOR and the blue protein is the CCR5, while compound 1b is colored in yellow.
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one general binding mode that may represent a lower affinity
mode. Within this binding mode there was an unstable binding
pocket for the triazole portion of the molecule that led to it adopt-
ing two different conformations during the simulation. These
observations were in agreement with the experimental data
observed. For the CCR5 calcium antagonism assays, the loss in
activity between maraviroc and compounds 1b and 3b can be
explained by the unstable triazole binding pocket. In comparison,
MOR calcium antagonism between naltrexone and compounds
1b and 2b was affected to a much lesser extent. During the simu-
lation, the naltrexone portion of 1b did not move from its original
binding pocket, which suggests that the 6b-attachment did not
notably affect MOR binding. To be noticed, during the dynamics
simulation, the maraviroc portion of 1b interacted with I198,
L255, N258, Q261, and M279. Among them I198 and L255 have
been deemed essential for maraviroc binding and N258 has been
implicated in HIV-1 gp120 binding.57,58 This could partially explain
the anti-HIV invasion effect of ligand 1b in the astrocytes.
Overall, the dynamics simulations indicated that 1bmay recog-
nize the putative CCR5–MOR heterodimer in an acceptable man-
ner. Furthermore, though the CCR5 binding mode might not be
optimal for 1b due to the limitation of our initial molecular design,
it still blocked gp120 mediated invasion/fusion as seen in both the
cell fusion assay and the HIV-1 invasion assay. Within the HIV-1
invasion assay, 1b showed even higher potency for inhibiting inva-
sion than maraviroc or a simple combination of maraviroc and nal-
trexone. Thus, the binding mode observed from our dynamics
simulations suggested an explanation for the observed enhance-
ment in inhibitory effects, as ligand 1b might simultaneously
bound to both the MOR and the CCR5 to contribute its inhibitory
effect on HIV invasion.
3. Conclusion
Bivalent ligands provide a new tool to study heterodimerization
of GPCRs. Targeting the putative CCR5–MOR heterodimer may be a
novel and potentially efficacious antiviral strategy to treat neu-
roAIDS. Among the ligands we designed, synthesized, and tested,
compound 1b has proven to be a potent inhibitor in both an artifi-
cial cell fusion assay mimicking HIV invasion and a native HIV
Figure 8. Trajectory of 1b in the CCR5–MOR heterodimer at 0, 2.4, 4.4, and 6.0 ns, with dark blue representing 1b at 0 ns and subsequently becoming a light blue at 6.0 ns.
Table 3
Major amino acids in the CCR5 and MOR binding pockets in the heterodimer
interacting with compound 1b
Time
frame
(ns)
CCR5 binding pocketa MOR binding pocket
0 W86, Y89, W94, T177, C178, S179, I198,
L255, N258, Q261, D276, M279
D147, Y148, N150,
M151, I293, H294, V297,
W315, I319, Y323
6 K22, E172, G173, Y184, K191, I198,
L255, N258, Q261, S272, N273, D276,
M279
D147, Y148, N150,
M151, I293, V236, H294,
W315, I319, Y323
a The residues in bold are consistent with site-directed mutagenesis data for
maraviroc binding.28,31 Italicized residues are important to HIV-1 gp120 binding.28
Bold-italicized residues are important to both maraviroc and gp120 binding via
results of site-directed mutagenesis data.
Figure 9. Different binding pocket (green) for the triazole moiety of 1b (yellow) at 0 ns and 6.0 ns.
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invasion assay using live virus. Importantly, in the native cell HIV
invasion assay, maraviroc was unable to inhibit HIV infection effec-
tively in the presence of morphine in primary human astrocytes.
However, compound 1b was a more potent inhibitor than maravi-
roc in primary human astrocytes with and without morphine (3.3-
fold higher virus inhibition than maraviroc without morphine, and
7-fold higher virus inhibition than maraviroc with morphine).
Utilizing molecular modeling and dynamics simulations, a possible
bindingmode of 1bwas postulated and helped explain the possible
mechanism of invasion inhibition by 1b. The intrinsic shortcoming
of our initial molecular design based on the homology model of
CCR5 at least partially rendered a less compelling affinity of com-
pound 1b to both receptors and their putative dimers. On the other
hand, as a proof-of-concept, this compound seems to be a promis-
ing lead to further develop more potent chemical probes to study
neuroAIDS by targeting such a dimer. In all, these results encour-
age us to pursue another wave of molecular design based on this
lead compound and the recently available crystal structure of
CCR5 bound to maraviroc.
4. Experimental
4.1. Chemical syntheses
Chemical reagents were purchased from Sigma–Aldrich, Alfa
Aesar, Combi-blocks, or AK Scientific and used without further
purification. TLC analyses were carried out on Analtech Uniplate
F254 plates. Chromatographic purification was accomplished on
silica gel columns (230–400 mesh, Bodman). IR spectra were
recorded on a Nicolet Avatar 360 FT-IR Instrument with ATR
attachment. 1H (400 MHz) and 13C (100 MHz) nuclear magnetic
resonance (NMR) spectra were acquired on a Bruker Ultrashield
400 Plus spectrometer. HREIMS analysis was performed on a
Quattro II triple quadrupole mass spectrometer, a Waters
Micromass QTOF-II instrument (ESI source), or an Applied Bio
Systems 3200 Q trap with a turbo V source for TurbolonSpray.
4.1.1. (E)-Isopropyl 3-(3-bromophenyl)acrylate (6)
3-Bromocinnamic acid (5 g, 22.02 mmol) was dissolved in
100 mL isopropyl alcohol in a round bottom flask. Several drops
of concentrated H2SO4 (100 lL) were added to the solution. The
mixture was refluxed at 120 C in an oil bath and monitored with
TLC. After 24 h the reaction mixture was cooled down to ambient
temperature and the solvent was evaporated. Ethyl acetate was
then added to dissolve the residue and washed with NaHCO3 (aq)
and dried over Na2SO4, filtered and purified using column chro-
matography. A total of 4.71 g 6 was received with a yield of 79%.
1H NMR (400 MHz, CDCl3) d 7.65 (t, J = 1.72 Hz, 1H), 7.56 (d,
J = 16.00 Hz, 1H), 7.47 (m, 1H), 7.41 (d, J = 7.76 Hz, 1H), 7.23 (t,
J = 7.86 Hz, 1H), 6.40 (d, J = 15.96 Hz, 1H), 5.14 (d, J = 6.28 Hz,
1H), 1.31 (d, J = 6.28 Hz, 6H); 13C NMR (100 MHz, CDCl3) d
165.95, 142.48, 136.67, 132.86, 130.69, 130.32, 126.57, 122.99,
120.37, 68.00, 21.91 (2). IR (ATR, cm1) mmax 3061, 2979, 2936,
2874, 1706, 1638, 1144, 1105.
4.1.2. (E)-Isopropyl 3-(3-aminophenyl)acrylate (7)
Compound 6 (4.71 g, 17.5 mmol) was dissolved in 60 mL anhy-
drous toluene. To it, in a stepwise manner, was added Pd2(dba)3
(0.801 g, 5%) and P(t-Bu)3 (0.142 g, 4%), and the mixture was
allowed to stir for 15 min under N2 protection. To the suspension,
LHMDS in toluene (19.25 mL, 1 M in toluene, 19.25 mmol) was
added dropwise and the reaction mixture was allowed to stir
overnight under N2 protection. An additional 2.5% Pd2(dba)3, 2% P
(t-Bu)3, and 0.5 equiv LHMDS was added subsequently to the
reaction mixture and stirred overnight under N2 protection. The
resulting reaction mixture was then quenched using 1 N HCl very
slowly over ice. The mixture was stirred for an additional 2 h and
filtered through celite and diluted with dichloromethane. The
organic layer was extracted and washed with saturated aqueous
NaHCO3, then brine and dried over Na2SO4. The crude product
was then purified using column chromatography to give 2.461 g
of title compound at a yield of 69%. 1H NMR (400 MHz, CDCl3) d
7.57 (d, J = 16.00 Hz, 1H), 7.14 (t, J = 7.80 Hz, 1H), 6.90 (d,
J = 7.60 Hz, 1H), 6.80 (m, 1H), 6.68 (m, 1H), 6.35 (d, J = 16.00 Hz,
1H), 5.12 (sep, J = 6.28, 1H), 3.74 (brs, 2H), 1.29 (d, J = 6.28 Hz,
6H); 13C NMR (100 MHz, CDCl3) d 166.63, 146.85, 144.63, 135.55,
129.73, 118.58, 118.56, 117.00, 114.12, 67.73, 21.95 (2). IR
(ATR, cm1) mmax 3457, 3420, 3369, 2979, 2935, 1694, 1633,
1458, 1271, 1173, 1103.
4.1.3. (E)-Isopropyl 3-(3-(tert-butoxycarbonylamino)phenyl)
acrylate (8)
Compound 7 (2.54 g, 12.4 mmol) was added to 30 mL H2O and
to it NaHCO3 (3.12 g, 24.8 mmol) was added and allowed to stir
for 10 min. The solution was cooled to 5 C and di-tert-butyl dicar-
bonate (4.06 g, 18.6 mmol) in 20 mL dioxane was added dropwise.
The resultant solution was cooled to 0 C for 1 h and allowed to stir
at ambient temperature overnight. The aqueous solution was then
washed with 50 mL of ethyl acetate and the organic layer was then
extracted with saturated NaHCO3 (aq). The aqueous layers were
then combined and acidified with 10% HCl to a final pH of 1. The
aqueous solution was then extracted with ethyl acetate, and the
organic layer was dried over Na2SO4 and concentrated. The crude
product was then purified with column chromatography and a
total of 2.884 g title compound was obtained with a yield of 76%.
1H NMR (400 MHz, CDCl3) d 7.65 (m, 1H), 7.62 (d, J = 16.08 Hz,
1H), 7.28 (m, 2H), 7.19 (m, 1H), 6.55 (brs, 1H), 6.42 (d,
J = 16.00 Hz, 1H), 5.13 (sep, J = 6.28 Hz, 1H), 1.53 (s, 9H), 1.30 (d,
J = 6.28 Hz, 6H); 13C NMR (100 MHz, CDCl3) d 166.43, 152.61,
144.03, 138.97, 135.46, 129.39, 122.73, 120.05, 119.34, 117.64,
80.81, 67.79, 28.33 (3), 21.93 (2). IR (ATR, cm1) mmax 3308,
3058, 2979, 2936, 1702, 1547, 1485, 1440, 1229, 1169, 1104.
4.1.4. (S)-Isopropyl 3-(benzyl((R)-1-phenylethyl)amino)-3-(3
(Tertbutoxycarbonylamino)phenyl) propanoate (9)
R-(+)-N-benzyl-a-methylbenzylamine (4.6 g, 21.8 mmol) was
dissolved in 30 mL anhydrous THF and stirred at 0 C under N2 pro-
tection. To it, n-butyl-lithium (8.76 mL, 2.5 M in hexane,
21.8 mmol) was added dropwise and stirred for 30 min. During
the addition, the reaction mixture went from being clear to a deep
purple color. The reaction mixture was then cooled down to 78 C
and 8 (2.68 g, 8.78 mmol) in 15 mL anhydrous THF was added
dropwise and allowed to stir for 2 h. Saturated NH4Cl (50 mL)
was then added to the reaction mixture and it was allowed to
warm up to ambient temperature over 1.5 h. Ethyl acetate was
then added to the reaction mixture and extracted. The organic
layer was then washed twice with 1 N HCl, dried over Na2SO4, fil-
tered, and concentrated. MeOH was then added to the residue and
then concentrated to get rid of any residual ethyl acetate. The title
compound was then recrystallized from hot MeOH and a total of
1.827 g was received with a 41% yield as the first crop. 1H NMR
(400 MHz, CDCl3) d 7.41 (d, J = 7.36 Hz, 2H), 7.38–7.27 (m, 6H),
7.25–7.20 (m, 4H), 7.17 (m, 1H), 7.08 (d, J = 7.56 Hz, 1H), 6.43
(brs, 1H), 4.79 (sep, J = 6.28 Hz, 1H), 4.39 (dd, J = 5.28, 9.68 Hz,
1H), 4.00 (q, J = 6.88 Hz, 1H), 3.68 (s, 2H), 2.65–2.45 (m, 2H), 1.53
(s, 9H), 1.26 (d, J = 6.84 Hz, 3H), 1.06 (d, J = 6.24 Hz, 3H), 1.00 (d,
J = 6.24 Hz, 3H); 13C NMR (100 MHz, CDCl3) d 171.30, 152.60,
144.07, 142.84, 141.55, 138.30, 137.50, 128.73, 128.12, 128.06,
127.88, 126.82, 126.54, 122.86, 118.26, 117.30, 80.40, 67.54,
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59.55, 57.09, 50.91, 46.25, 37.82, 28.37 (3), 21.59, 21.58, 16.27. IR
(ATR, cm1) mmax 3380, 2977, 2933, 2162, 1723, 1614, 1540, 1155.
MS (ESI) m/z calcd 517.3061, found 517.113 (M+H)+.
4.1.5. (S)-3-(Benzyl((R)-1-phenylethyl)amino)-3-(3-(tert-butoxy-
carbonylamino)phenyl) propanoic acid (10)
Compound 9 (1.4 g, 2.71 mmol) was dissolved in a 2:1 mixture
of MeOH/H2O (30 mL). To it LiOH (0.32 g, 13.55 mmol) was added
while the reaction was stirring. The suspension was then refluxed
(85 C) using a preheated oil bath under N2 protection overnight.
The reaction mixture was allowed to cool to ambient temperature
and was adjusted to pH = 1 using 10% HCl. The solution was then
extracted with dichloromethane three times and the resulting
organic layers were dried over Na2SO4, filtered, and concentrated.
No additional purification was required and a total of 1.12 g title
compound was received with 88% yield. 1H NMR (400 MHz, CDCl3)
d 7.47 (brs, 1H), 7.35–7.32 (m, 6H), 7.32–7.26 (m, 5H), 7.23 (m, 1H),
7.04 (m, 1H), 6.64 (brs, 1H), 4.42 (dd, J = 5.2, 10.28 Hz, 1H), 4.18 (q,
J = 6.88 Hz, 1H), 4.00 (d, J = 13.8 Hz, 1H), 3.71 (d, J = 13.8 Hz, 1H),
2.88 (dd, J = 10.3, 16.76 Hz, 1H), 2.45 (dd, J = 5.2, 16.76 Hz, 1H),
1.54 (s, 9H), 1.28 (d, J = 6.92 Hz, 3H); 13C NMR (100 MHz, CDCl3)
d 172.06, 161.25, 152.75, 143.24, 140.60, 139.01, 128.47, 128.10
(2), 128.04 (2), 127.93 (2), 127.74 (2), 126.92, 126.61,
122.12, 118.65, 117.40, 79.32, 58.44, 57.20, 49.89, 34.60, 27.27
(3), 15.89. IR (ATR, cm1) mmax 3293, 2978, 2931, 2520, 1713,
1594, 1495, 1154.
4.1.6. tert-Butyl (3-((1S)-1-(benzyl((R)-1-phenylethyl)amino)-3-
(-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo
[3.2.1]octan-8-yl)-3-oxopropyl)phenylcarbamate (12)
In a 25 mL flask, acid 10 (600 mg, 1.264 mmol) was dissolved in
6 mL anhydrous dichloromethane. To the solution N-(3-dimethy-
laminopropyl)-N0-ethylcarbodiimide hydrochloride (364 mg,
1.8965 mmol), 1-hydroxybenzotriazole hydrate (256 mg,
1.8965 mmol), triethylamine (0.54 mL, 3.793 mmol), and 4 Å
molecular sieves were added and stirred under nitrogen protection
at 0 C for 0.5 h. 3-(3-Isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-
azabicyclo[3.2.1]octane 111 (314 mg, 1.5172 mmol) was then
added to the reaction mixture and allowed to proceed to ambient
temperature over the period of 96 h, and monitored via TLC. Once
completed, the reaction mixture was filtered and the solvent was
evaporated under reduced pressure. The reaction mixture was then
washed once with brine. The organic layer was dried over anhy-
drous sodium sulfate, filtered and evaporated under reduced pres-
sure. Column chromatography was then conducted and a total of
645 mg of the title compound as a mixture of atropisomers (with
a ratio of 2:3 based on 1H NMR) was received in 74% yield. 1H
NMR (400 MHz, CDCl3) d 7.61 (brs, 0.4H), 7.49 (d, J = 7.92 Hz,
1H), 7.48 (brs, 0.6H), 7.44 (d, J = 7.56 Hz, 1H), 7.35–7.10 (m, 11H),
6.67 (s, 0.6H), 6.65 (s, 0.4H), 4.71 (m, 0.4H), 4.67–4.55 (m, 1H),
4.45 (dd, J = 4.12, 10.52 Hz, 0.6H), 4.36 (m, 1H), 4.02 (qu,
J = 6.74 Hz, 1H), 3.90–3.65 (m, 3H), 2.83 (sep, J = 6.60 Hz, 1H),
2.68–2.52 (m, 1.4H), 2.48 (dd, J = 4.16, 13.92 Hz, 0.6H), 2.27 (s,
1.8H), 2.19 (brs, 0.4H), 2.12 (s, 1.2H), 2.10–2.05 (m, 1.6H), 1.89
(m, 1H), 1.80–1.60 (m, 4H), 1.53–1.45 (m, 10H), 1.37–1.25 (m,
9H); 13C NMR (100 MHz, CDCl3) d 167.21 (166.98), 158.88
(158.76), 152.64 (152.60), 150.41 (150.56), 144.25 (144.36),
143.02 (143.38), 142.09, 138.59 (138.65), 129.03 (128.94), 128.19
(128.15), 128.09 (128.04), 127.92 (2), 126.79 (126.70), 126.61
(126.54), 122.92, 117.99 (118.11), 117.39 (117.30), 80.41, 61.33,
59.78, 56.43 (56.72), 53.87, 51.16 (50.77), 50.53 (50.62), 46.67,
38.46 (37.88), 37.51 (37.68), 35.75 (35.63), 28.37 (3), 28.26
(28.43), 26.64 (26.89), 25.83 (25.77), 21.65 (21.51), 21.57 (2),
13.97 (14.79), 13.10 (13.01). IR (ATR, cm1) mmax 3247, 2973,
2932, 2185, 2050, 1716, 1632, 1529, 1436, 1158.
4.1.7. tert-Butyl (3-((1S)-1-amino-3-(3-(3-isopropyl-5-methyl-
4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)-3-oxopro-
pyl)phenylcarbamate (13)
In a 250 mL hydrogenation flask, acetic acid (0.166 mL,
2.9 mmol) was added to 60 mL MeOH. To that, 1-(trifluo-
romethyl)-4-(4-isopropoxy-3-nitrophenyl)piperazine (1.0 g,
1.45 mmol) was added to the solution along with 10% w/w palla-
dium on carbon (0.2 g). The flask was placed on a hydrogenator
at 60 psi H2 gas for 48 h, and monitored via TLC. Once completed,
the reaction mixture was vacuum filtered through celite, and then
evaporated under reduced pressure. Column chromatography was
then conducted and a total of 0.66 g of the title compounds as a
mixture of atropisomers (with a ratio of 1:1) was received with a
final yield of 91%. 1H NMR (400 MHz, CDCl3) d 7.55 (s, 0.5 H),
7.48 (s, 0.5H), 7.25–7.15 (m, 2H), 7.08 (m, 1H), 6.70 (brs, 1H),
4.88 (m, 1H), 4.53 (m, 2H), 4.28 (m, 1H), 2.93 (sep, J = 6.84 Hz,
1H), 2.76–2.54 (m, 2H), 2.45 (s, 1.5H), 2.36 (s, 1.5H), 2.44–1.62
(m, 10H), 1.51 (s, 9H), 1.39 (m, 6H); 13C NMR (100 MHz, CDCl3) d
166.64 (166.60), 158.90, 153.03 (152.96), 150.96, 150.53, 139.17,
129.45, 121.16, 118.45 (118.35), 117.10 (117.06), 80.47 (80.38),
53.89 (53.83), 52.68, 52.57, 51.01, 50.97, 50.47, 50.42, 46.88
(46.78), 37.58 (37.45), 35.88 (35.74), 28.32 (3), 26.86, 25.80
(25.72), 21.59 (21.54), 21.49, 13.29 (13.08). IR (ATR, cm1) mmax
3256, 2973, 2933, 2879, 2162, 1715, 1610, 1440, 1158. MS (ESI)
m/z calcd 497.3235, found 497.162 (M+H)+.
4.1.8. tert-Butyl (3-((1S)-1-amino-3-(3-(3-isopropyl-5-methyl-
4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)propyl)
phenylcarbamate (14)
Lithium aluminum hydride (191 mg, 5.035 mmol) was added to
15 mL anhydrous THF at 0 C under N2 protection. Compound 13
(500 mg, 1.007 mmol) was dissolved in 15 mL anhydrous THF
and then added dropwise to the above suspension. The resultant
mixture was stirred at 0 C for 15 min and then allowed to reach
ambient temperature over a 3 h period. The reaction mixture was
then cooled to 0 C in an ice bath and quenched with the sequential
addition of 0.2 mL H2O, 0.2 mL 4 N NaOH, and then 0.6 mL H2O and
stirred at ambient temperature for 1 h. The suspension was filtered
and the filtrate was washed with THF and diethyl ether. The
organic filtrates were combined, dried over Na2SO4, filtered, and
then evaporated to dryness. After column chromatography, a total
of 0.38 g title compound was obtained with a yield of 79%. 1H NMR
(400 MHz, CDCl3) d 7.51 (s, 1H), 7.25 (t, J = 7.84 Hz, 1H), 7.11 (dd,
J = 1.22, 7.98 Hz, 1H), 7.00 (d, J = 7.60 Hz, 1H), 6.50 (brs, 1H), 4.29
(m, 1H), 4.06 (t, J = 6.64 Hz, 1H), 3.39 (m, 2H), 2.99 (sep,
J = 6.80 Hz, 1H), 2.48 (s, 3H), 2.43 (t, J = 6.94 Hz, 1H), 2.21 (m,
2H), 2.05 (m, 2H), 1.90–1.55 (m, 9H), 1.51 (s, 9H), 1.38 (d,
J = 6.84 Hz, 1H). IR (ATR, cm1) mmax 3362, 2931, 2875, 1159,
1016, 915.
4.1.9. 4,4-Difluorocyclohexanecarboxylic acid (15)
Ethyl 4-oxycyclohexanecarboxylate (1.13 g, 6.67 mmol) was
dissolved in anhydrous dichloromethane (10 mL) in a high density
polyethylene (HDPE) container. To it, 4-tert-butyl-2,6-
dimethylphenylsulfur trifluoride (2.5 g, 9.99 mol) was added and
stirred under N2 at 0 C. HF-pyridine (0.64 mL, 2.64 mmol) was
added to the vessel and the reaction was allowed to reach ambient
temperature. After 5 h, the reaction mixture was quenched with
saturated aqueous NaHCO3. The organic layer was allowed to stir
at ambient temperature in 2 N NaOH for 1 h. The aqueous layer
was washed with dichloromethane and then acidified to pH 1
and extracted with dichloromethane. A total of 0.435 g title com-
pound was obtained at 27% yield. 1H NMR (400 MHz, CDCl3) d
2.498–2.278 (m, 1H), 1.984–1.881 (m, 4H), 1.872–1.753 (m, 4H).
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4.1.10. tert-Butyl (3-((1S)-1-(4,4-difluorocyclohexanecarbox-
amido)-3-(3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-
azabicyclo[3.2.1]octan-8-yl)propyl)phenylcarbamate (16)
In a 10 mL flask, acid 15 (132 mg, 0.801 mmol) was dissolved in
2 mL anhydrous dichloromethane. To the solution N-(3-dimethy-
laminopropyl)-N0-ethylcarbodiimide hydrochloride (177 mg,
0.924 mmol), 1-hydroxybenzotriazole hydrate (125 mg,
0.924 mmol), triethylamine (0.26 mL, 1.848 mmol), and 4 Å molec-
ular sieves were added and stirred under nitrogen protection at
0 C for 0.5 h. Compound 14 (300 g, 0.616 mmol) was then added
to the reaction mixture and allowed to proceed to ambient temper-
ature over the period of 48 h, and monitored via TLC. Once com-
pleted, the reaction mixture was filtered, washed with brine,
dried over Na2SO4. The solvent was evaporated under reduced
pressure. Column chromatography was then conducted and a total
of 0.234 g of a yellow oil title compound was received with a final
yield of 60%. 1H NMR (400 MHz, CDCl3) d 7.55 (s, 1H), 7.24 (t,
J = 8.00 Hz, 1H), 7.08 (dd, J = 1.26, 8.02 Hz, 1H), 6.93 (d,
J = 7.64 Hz, 1H), 6.60 (m, 2H), 5.10 (q, J = 6.80 Hz, 1H), 4.30 (sep,
J = 5.68 Hz, 1H), 3.39 (m, 2H), 2.98 (sep, J = 6.84 Hz, 1H), 2.51 (s,
3H), 2.43 (t, J = 6.48 Hz, 2H), 2.30–2.10 (m, 5H), 2.06 (m, 2H),
2.03–1.88 (m, 4H), 1.88–1.55 (m, 8H), 1.51 (s, 9H), 1.39 (d,
J = 6.80 Hz, 6H); 13C NMR (100 MHz, CDCl3) d 173.24, 159.14,
152.67, 150.63, 142.98, 138.94, 129.29, 121.16, 117.41, 117.41,
116.23, 80.63, 58.79, 58.16, 53.43, 52.20, 47.66, 47.26, 42.89,
35.31, 35.12, 34.69, 33.04, 32.79, 32.55, 28.34 (3), 26.84, 26.01,
25.92, 25.87, 21.66 (2), 13.22. IR (ATR, cm1) mmax 3257, 2968,
2936, 2875, 2162, 1980, 1717, 1656, 1527, 1444, 1367, 1237,
1159. MS (ESI) m/z calcd 629.3985, found 629.292 (M+H)+.
4.1.11. N-((1S)-1-(3-Aminophenyl)-3-(3-(3-isopropyl-5-methyl-
4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl)propyl)-4,4-
difluorocyclohexanecarboxamide (5)
Compound 16 (200 mg, 0.3181 mmol) was dissolved in 5 mL
anhydrous dichloromethane and stirred at 0 C. To the solution, tri-
fluoroacetic acid (0.5 mL) was added dropwise and the solution
was allowed to reach ambient temperature and stirred for 2 h.
The solution was then cooled to 0 C in an ice bath and saturated
aqueous Na2CO3 was added and the aqueous layer was adjusted
to pH 12 and extracted three times with dichloromethane. The
combined organic layers were then washed with brine, dried over
Na2SO4, filtered, and evaporated to dryness. A total of 0.215 g title
compound of yellow oil was received with quantitative yield. 1H
NMR (400 MHz, CDCl3) d 7.70 (m, 1H), 7.53 (m, 1H), 7.13 (t,
J = 7.80 Hz, 1H), 6.66 (d, J = 7.68 Hz, 1H), 6.38 (d, J = 6.56 Hz, 1H,
exchangeable), 5.01 (qu, J = 6.96 Hz, 1H), 4.29 (m, 1H), 3.70 (brs,
2H, exchangeable), 3.39 (m, 2H), 2.98 (seq, J = 6.88 Hz, 1H), 2.50
(s, 3H), 2.43 (m, 2H), 2.30–2.02 (m, 7H), 2.02–1.72 (m, 8H), 1.72–
1.52 (m, 4H), 1.38 (d, J = 6.84 Hz, 6H); 13C NMR (100 MHz, CDCl3)
d 173.15, 159.13, 150.62, 146.86, 143.04, 132.47, 122.57 (JCF
239.9 Hz), 116.26, 114.32, 113.37, 58.76, 58.23, 52.13, 47.81,
47.25, 42.95, 35.31, 35.16, 34.71, 32.83 (2JCF 24.4 Hz), 26.83,
26.00 (3JCF 9.6 Hz), 25.86, 21.66, 13.19. IR (ATR, cm1) mmax 3318,
3224, 2957, 2932, 2873, 2177, 1724, 1651, 1520, 1456, 1345, 1106.
4.1.12. Benzyl 5-aminopentylcarbamate (17a)
On an ice-water bath, to the solution of cadaverine (1.022 g,
10 mmol) in dichloromethane (250 mL) was added the solution
of benzyl chloroformate (853 mg, 5 mmol) in dichloromethane
(50 mL) dropwise within 12 h while keeping the temperature
below 5 C. The reaction mixture was then concentrated to
50 mL. Water (50 mL) was added, and the aqueous layer was
adjusted to pH = 2 using 6 N HCl. The layers were separated. The
aqueous layer was washed with dichloromethane (50 mL  3),
then adjusted to pH = 12 with 10 N NaOH and extracted with
dichloromethane (50 mL  3). The combined organic layers were
dried over Na2SO4, concentrated and purified by flash column
using dichloromethane/MeOH to give 710 mg white semi-solid in
60% yield. 1H NMR (400 MHz, CDCl3) d 7.35 (m, 5H), 5.10 (s, 2H),
4.79 (brs, 1 H), 3.19 (m, 2H), 2.69 (m, 2H), 1.50–1.47 (m, 4H),
1.36 (m, 2H); 13C NMR (100 MHz, CDCl3) d 156.49, 136.74,
128.45 (2), 128.00 (2), 66.51, 41.73, 40.95, 32.77, 29.74, 23.92.
IR (ATR, cm1) mmax 3328, 2922, 2852, 1686, 1537, 1266, 1248, 697.
4.1.13. Benzyl 7-aminononylcarbamate (17b)
Previously reported.23
4.1.14. Benzyl 9-aminononylcarbamate (17c)
The title compound was prepared in a similar way as 17a in 62%
yield. 1H NMR (400 MHz, CDCl3) d 7.34 (m, 5H), 5.09 (s, 2H), 4.82
(brs, 1H), 3.18 (q, J = 6.16 Hz, 2H), 2.67 (m, 2H), 1.49 (m, 2H),
1.42 (m, 2H), 1.29 (m, 10H); 13C NMR (100 MHz, CDCl3) d 156.41,
136.76, 128.47 (3), 128.02 (2), 66.54, 42.24, 41.11, 33.84,
29.96, 29.46, 29.37, 29.17, 26.83, 26.69. Mp 41–43 C. IR (ATR,
cm1) mmax 3342, 2922, 2850, 1683, 1527, 1255, 1235, 1023, 726,
694.
4.1.15. [(9-Benzyloxycarbonylamino-pentylcarbamoyl)-
methoxy]acetic acid (18a)
To the solution of 17a (520 mg, 2.20 mmol) in THF (20 mL) was
added diglycolic anhydride (268 mg, 2.31 mmol) in one portion.
The resultant mixture was stirred at ambient temperature for
12 h. After removing THF under reduced pressure, the residue
was crystallized with EtOAc/hexane to give 493 mg white solid
as first crop, in 64% yield. 1H NMR (400 MHz, DMSO-d6) d 12.74
(brs, 1H), 7.79 (m, 1H), 7.38–7.30 (m, 5 H), 7.18 (m, 1H), 5.00 (s,
2H), 4.09 (s, 2H), 3.94 (s, 2H), 3.08 (q, J = 6.39 Hz, 2H), 2.97 (q,
J = 6.31 Hz, 2H), 1.42–1.38 (m, 4H), 1.23 (m, 2H); 13C NMR
(100 MHz, DMSO-d6) d 171.37, 168.54, 156.06, 137.30, 128.29
(3), 127.67 (2), 70.21, 67.93, 65.06, 38.05, 29.02, 28.74 (2),
23.57. Mp 71–71.5 C. IR (ATR, cm1) mmax 3358, 3311, 2930,
1686, 1552, 1266, 1216, 1131, 692.
4.1.16. 3,13-Dioxo-1-phenyl-2,15-dioxa-4,12-diazaheptadecan-
17-oic acid (18b)
Previously reported.23
4.1.17. 3,15-Dioxo-1-phenyl-2,17-dioxa-4,14-diazanonadecan-
19-oic acid (18c)
The title compound was prepared in a similar way as 18a in 73%
yield. 1H NMR (400 MHz, DMSO-d6) d 7.86 (m, 0.5H), 7.73 (m,
0.5H), 7.38–7.28 (m, 5 H), 7.18 (m, 1H), 5.00 (s, 2H), 4.20 (s, 1H),
4.08 (s, 1H), 3.94 (s, 1H), 3.93 (s, 1H), 3.66 (s, 1H), 3.08 (q,
J = 6.60 Hz, 2H), 2.97 (q, J = 6.66 Hz, 2H), 1.39 (m, 4H), 1.24 (m,
10H); 13C NMR (100 MHz, DMSO-d6) d 171.40, 168.56, 168.20,
156.05, 137.33, 128.28, 127.66, 127.62, 70.28, 70.14, 68.11, 67.75,
65.03, 51.45, 38.10, 29.04, 28.86, 28.61, 26.30, 26.16. Mp 37–
38 C. IR (ATR, cm1) mmax 3338, 2924, 1682, 1645, 1528, 1235,
1138, 696.
4.1.18. 17-Cyclopropylmethyl-3,14b-dihydroxy-4,5a-epoxy-6b-
(30,110-dioxo-10-phenyl-20,130-dioxa-40,100-diazapentadecan-
amido)morphinan (19a)
The title compound was prepared according to the general
amide coupling procedure by reacting acid 18awith 6b-naltrexam-
ine hydrochloride1 42HCl in DMF overnight. The crude product
was purified with chromatography using CH2Cl2/MeOH as eluent
to give 667 mg white solid, in 70% yield. 1H NMR (400 MHz, CD3-
OD) d 7.30–7.25 (m, 5H), 6.65 (d, J = 8.12 Hz, 1H), 6.59 (d,
J = 8.16 Hz, 1H), 5.06 (s, 2H), 4.54 (d, J = 7.56 Hz, 1H), 4.05 (s, 2H),
4.04 (s, 2H), 3.79–3.72 (m, 1H), 3.28–3.24 (m, 3H), 3.14–3.09 (m,
3H), 2.73–2.69 (m, 2H), 2.54–2.43 (m, 2H), 2.33–2.21 (m, 2H),
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1.92 (m, 1H), 1.60–1.33 (m, 10H), 0.91 (m, 1H), 0.56 (m, 2H), 0.20
(m, 2H); 13C NMR (100 MHz, CDCl3) d 171.62, 171.48, 158.95,
143.82, 142.02, 138.52, 132.28, 129.46, 128.94, 128.74, 124.97,
120.21, 118.80, 92.84, 71.68, 71.62, 67.34, 63.94, 60.12, 52.47,
45.71, 41.70, 40.00, 31.60, 31.20, 30.53, 30.09, 25.31, 25.10,
23.73, 9.86, 4.68, 4.10. Mp 80–83 C. IR (ATR, cm1) mmax 3296,
2934, 1655, 1538, 1242, 1128, 1035, 697.
4.1.19. 17-Cyclopropylmethyl-3,14b-dihydroxy-4,5a-epoxy-6b-
(30,130-dioxo-10-phenyl-20,150-dioxa-40,120-diazaheptadecan-
amido)morphinan (19b)
Previously reported.23
4.1.20. 17-Cyclopropylmethyl-3,14b-dihydroxy-4,5a-epoxy-6b-
(30,150-dioxo-10-phenyl-20,170-dioxa-40,140-diazanonadecan-
amido)morphinan (19c)
The title compound was prepared in a similar way as 19a in 63%
yield. 1H NMR (400 MHz, CD3OD) d 7.33–7.23 (m, 5H), 6.65 (d,
J = 8.12 Hz, 1H), 6.58 (d, J = 8.12 Hz, 1H), 5.05 (s, 2H), 4.54 (d,
J = 7.52 Hz, 1H), 4.06 (s, 2H), 4.05 (s, 2H), 3.76 (m, 1H), 3.26 (t,
J = 7.14 Hz, 2H), 3.20 (m, 1H), 3.13–3.07 (m, 3H), 2.73–2.66 (m,
2H), 2.52 (m, 1H), 2.43 (m, 1H), 2.32–2.18 (m, 2H), 1.91 (m, 1H),
1.62–1.41 (m, 8H), 1.31 (m, 10H), 0.90 (m, 1H), 0.60–0.51 (m,
2H), 0.23–0.17 (m, 2H); 13C NMR (100 MHz, CDCl3) d 171.54,
171.45, 158.91, 143.82, 142.00, 138.55, 132.30, 129.47 (2),
128.94, 128.75 (2), 125.07, 120.22, 118.80, 92.87, 71.68 (2),
71.62, 67.31, 63.91, 60.14, 52.45, 48.75, 45.66, 41.88, 40.16,
31.68, 31.21, 30.91, 30.55, 30.48, 30.32 (2), 27.99, 27.79, 25.33,
23.73, 9.89, 4.70, 4.17. Mp 70–72 C. IR (ATR, cm1) mmax 3304,
2929, 2857, 1652, 1557, 1453, 1247, 1128, 1034, 742.
4.1.21. 17-Cyclopropylmethyl-3,14b-dihydroxy-4,5a-epoxy-6b-
(20-(20-(50-aminopentylamino)-20-oxoethoxy)acetamido)mor-
phinan (20a)
A solution of 19a (494 mg, 0.73 mmol) in methanol (20 mL) was
hydrogenated in the presence of 10% Pd/C (50 mg) under a H2
atmosphere (60 psi) at room temperature for 6 h. The mixture
was filtered, and the filtrate was concentrated and crystallized
with MeOH/Et2O to give 20a as white solid (352 mg, 89% yield).
1H NMR (400 MHz, CD3OD) d 6.63 (d, J = 8.12 Hz, 1H), 6.57 (d,
J = 8.16 Hz, 1H), 4.51 (d, J = 7.64 Hz, 1H), 4.07 (s, 2H), 4.06 (s, 2H),
3.75 (m, 1H), 3.29 (m, 2H), 3.12 (d, J = 5.76 Hz, 1H), 3.08 (d,
J = 18.64 Hz, 1H), 2.78 (t, J = 7.34 Hz, 2H), 2.70–2.61 (m, 2H),
2.48–2.36 (m, 2H), 2.29–2.21 (m, 1H), 2.19–2.10 (m, 1H), 1.91
(m, 1H), 1.63–1.37 (m, 10H), 0.88 (m, 1H), 0.54 (m, 2H), 0.16 (m,
2H); 13C NMR (100 MHz, CD3OD) d 171.75, 171.47, 143.79,
142.08, 132.50, 125.41, 120.12, 118.70, 92.98, 71.74, 71.62, 63.82,
60.30, 52.57, 49.84, 45.30, 41.60, 39.80, 31.98, 31.27, 31.06,
30.10, 25.48, 24.98, 23.59, 10.28, 4.44, 4.19. Mp 145–148 C. IR
(ATR, cm1) mmax 3275, 2929, 1652, 1552, 1323, 1130, 1036.
4.1.22. 17-Cyclopropylmethyl-3,14b-dihydroxy-4,5a-epoxy-6b-
20-[20 0-(70 0-aminoheptylamino)-20-oxoethoxy]acetamidomor-
phinan (20b)
Previously reported.23
4.1.23. 17-Cyclopropylmethyl-3,14b-dihydroxy-4,5a-epoxy-6b-
20-[20 0-(90 0-aminononylamino)-20-oxoethoxy]acetamidomor-
phinan (20c)
The title compound was prepared in a similar way as 20a in 64%
yield (first crop). 1H NMR (400 MHz, CD3OD) d 6.63 (d, J = 8.12 Hz,
1H), 6.56 (d, J = 8.16 Hz, 1H), 4.51 (d, J = 7.56 Hz, 1H), 4.06 (s, 2H),
4.05 (s, 2H), 3.76 (m, 1H), 3.26 (t, J = 7.12 Hz, 2H), 3.12–3.05 (m,
2H), 2.72–2.60 (m, 4H), 2.40 (m, 2H), 2.25 (m, 1H), 2.15 (m, 1H),
1.90 (m, 1H), 1.59–1.43 (m, 8H), 1.30 (m, 10H), 0.87 (m, 1H),
0.54–0.50 (m, 2H), 0.18–0.14 (m, 2H); 13C NMR (100 MHz, CD3OD)
d 171.57, 171.43, 143.85, 142.17, 132.48, 125.34, 120.10, 118.74,
92.96, 71.74, 71.62, 71.57, 63.82, 60.33, 52.50, 48.93, 45.28,
42.00, 40.10, 32.14, 32.06, 31.25, 30.48, 30.45, 30.36, 30.27,
27.94, 27.79, 25.46, 23.58, 10.32, 4.46, 4.23. Mp 125–128 C. IR
(ATR, cm1) mmax 3274, 2928, 1652, 1557, 1323, 1129, 1035, 743.
4.1.24.17-Cyclopropylmethyl-3,14b-dihydroxy-4,5a-epoxy-6b-
(10-carboxy-40,120-dioxo-20,140-dioxa-50,110-diazahexaadecan-
amido)morphinan (21a)
To the solution of 20a (311 mg, 0.61 mmol) in THF (2 mL) was
added diglycolic anhydride (71 mg, 0.61 mmol) in one portion.
The resultant mixture was stirred at ambient temperature for over-
night. After removal of THF under reduced pressure, the residue
was crystallized by MeOH/Et2O to give 381 mg light yellow solid,
in 95% yield. 1H NMR (400 MHz, DMSO-d6) d 8.28 (d, J = 8.44 Hz,
1H, exchangeable), 8.20 (m, 1H, exchangeable), 8.07 (t,
J = 5.80 Hz, 1H, exchangeable), 6.62 (d, J = 8.04 Hz, 1H), 6.55 (d,
J = 8.12 Hz, 1H), 4.64 (d, J = 7.76 Hz, 1H), 4.03 (s, 2H), 3.95 (s, 2H),
3.935 (s, 2H), 3.928 (s, 2H), 3.51 (m, 1H), 3.26 (m, 2H), 3.17–3.04
(m, 5H), 2.75–2.61 (m, 3H), 2.24 (m, 1H), 2.11 (m, 1H), 1.81 (m,
1H), 1.54–1.41 (m, 6H), 1.34–1.20 (m, 4H), 0.90 (m, 1H), 0.51 (m,
2H), 0.20 (m, 2H); 13C NMR (100 MHz, DMSO-d6) d 171.80,
168.85, 168.47, 168.28, 142.11, 140.68, 130.84, 122.64, 118.58,
117.30, 90.31, 70.59, 70.44, 69.58, 68.87, 61.82, 57.97, 50.56,
48.56, 46.63, 44.37, 38.09, 38.06, 29.91, 29.50, 28.84, 28.69,
24.32, 23.75, 22.43, 8.24, 3.97, 3.33. Mp 156–157 C. IR (ATR,
cm1) mmax 3395, 2935, 1655, 1559, 1123, 1035.
4.1.25. 17-Cyclopropylmethyl-3,14b-dihydroxy-4,5a-epoxy-6b-
(10-carboxy-40,140-dioxo-20,160-dioxa-50,130-diazaicosanamido)-
morphinan (21b)
Previously reported.23
4.1.26. 17-Cyclopropylmethyl-3,14b-dihydroxy-4,5a-epoxy-6b-
(10-carboxy-40,160-dioxo-20,180-dioxa-50,150-diazaicosanamido)-
morphinan (21c)
The title compound was prepared in a similar way as 21a in 99%
yield. 1H NMR (400 MHz, DMSO-d6) d 9.14 (brs, 1H, exchangeable),
8.26 (d, J = 8.36 Hz, 1H, exchangeable), 8.10 (m, 1H, exchangeable),
8.04 (t, J = 5.78 Hz, 1H, exchangeable), 6.61 (d, J = 8.08 Hz, 1H), 6.55
(d, J = 8.08 Hz, 1H), 4.63 (d, J = 7.76 Hz, 1H), 4.03 (s, 2H), 3.94 (s,
2H), 3.93 (m, 4H), 3.52 (m, 1H), 3.21 (m, 2H), 3.18–3.00 (m, 6H),
2.73–2.64 (m, 2H), 2.22 (m, 1H), 2.09 (m, 1H), 1.81 (m, 1H),
1.52–1.30 (m, 6H), 1.25 (m, 12H), 0.90 (m, 1H), 0.50 (m, 2H),
0.19 (m, 2H); 13C NMR (100 MHz, DMSO-d6) d 171.72, 168.78,
168.39, 168.25, 142.09, 140.65, 130.89, 122.77, 118.56, 117.25,
90.33, 70.42, 70.38, 69.58, 68.72, 61.79, 58.03, 56.00, 50.57,
46.69, 44.27, 38.15, 38.11, 29.95, 29.60, 29.17, 29.01, 28.84,
28.62, 26.34, 26.29, 24.35, 22.40, 18.52, 8.39, 3.92, 3.35. Mp 150–
151 C. IR (ATR, cm1) mmax 3236, 2929, 1645, 1604, 1545, 1318,
1127.
4.1.27. Bivalent ligand 1a
The title compound was prepared following the general proce-
dure by reacting 4-aminomaraviroc1 (60 mg, 0.1135 mmol) with
21a (112 mg, 0.170 mmol) in 49% yield. Hydrochloride salt: 1H
NMR (400 MHz, CD3OD) d 7.64 (d, J = 8.52 Hz, 2H), 7.42 (d,
J = 8.52 Hz, 2H), 6.76 (d, J = 8.2 Hz, 1H), 6.72 (d, J = 8.28 Hz, 1H),
4.98 (m, 1H), 4.69 (m, 2H), 4.32 (m, 1H), 4.24 (m, 3H), 4.16 (s,
2H), 4.10 (m, 4H), 3.94 (d, J = 5.72 Hz, 1H), 3.71 (m, 2H), 3.40–
3.32 (m, 3H), 3.25–3.00 (m, 9H), 2.95–2.55 (m, 8H), 2.52–2.38
(m, 4H), 2.36–2.15 (m, 4H), 2.15–1.73 (m, 9H), 1.68–1.49 (m,
7H), 1.47–1.30 (m, 7H), 1.14–1.08 (m, 2H), 0.82 (m, 1H), 0.74 (m,
1H), 0.55–0.49 (m, 2H), 0.29 (m, 2H); 13C NMR (100 MHz, CD3OD)
d 177.86, 171.87, 171.76, 171.74, 170.32, 143.78, 143.10, 138.59,
138.49, 130.77, 128.40 (2), 122.02 (2), 121.90, 121.01, 119.68,
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91.90, 71.84, 71.63, 71.45, 71.39 (2), 64.84, 64.32, 63.58, 62.69,
58.82, 52.44, 51.73, 50.39, 47.62, 43.46, 39.98, 39.93, 35.01, 33.82
(2JCF 24.3 Hz, 2), 32.00, 31.14, 29.88 (2), 28.91, 27.22, 27.16,
27.12, 26.67, 25.12, 24.87, 24.68, 24.49, 21.80 (3JCF 4.92 Hz, 2),
15.43, 12.19, 6.88, 6.18, 3.47. IR (ATR, cm1) mmax 3251, 2941,
1645, 1452, 1127, 1109, 1035. Mp 214–217 C. HRMS (ESI) m/z
calcd 1169.6569, found 1169.6567 (M+H)+, 585.3308 (M+2H)2+.
4.1.28. Bivalent ligand 1b
Previously reported.23
4.1.29. Bivalent ligand 1c
The title compound was prepared following the general proce-
dure by reacting 4-aminomaraviroc (40 mg, 0.0666 mmol) with
21c (71 mg, 0.0999 mmol) in 81% yield. Free base: 1H NMR
(400 MHz, CD3OD) d 7.64 (d, J = 8.52 Hz, 2H), 7.40 (d, J = 8.56 Hz,
2H), 6.74 (AB, J = 8.24 Hz, 2H), 4.99 (m, 1H), 4.69 (d, J = 7.92 Hz,
1H), 4.57 (m, 1H), 4.22 (s, 2H), 4.14 (s, 2H), 4.07 (m, 4H), 3.94 (d,
J = 5.72 Hz, 1H), 3.71 (m, 1H), 3.39–3.34 (m, 3H), 3.28–3.23 (m,
4H), 3.21–3.08 (m, 4H), 2.88 (s, 2H), 2.80–2.50 (m, 7H), 2.50–2.28
(m, 5H), 2.28–2.05 (m, 6H), 2.05–1.71 (m, 9H), 1.70–1.45 (m,
8H), 1.42–1.29 (m, 15H), 1.12 (m, 1H), 0.82 (m, 1H), 0.74 (m,
1H), 0.51 (m, 2H); 13C NMR (100 MHz, CD3OD) d 171.72 (2),
171.60, 170.25, 161.64, 160.48, 143.81, 143.11, 138.59, 130.78,
128.40 (2), 122.05 (2), 121.91, 120.99, 119.73, 91.94, 71.90,
71.70, 71.56, 71.48, 71.42 (2), 64.42, 58.88, 56.54, 52.44, 51.78,
47.64, 43.48, 43.39, 40.11, 40.10, 37.29, 35.95, 35.49, 33.82 (2JCF
24.4 Hz, 2), 31.15, 30.35 (2), 30.32, 30.12 (2), 28.96, 27.82,
27.80, 27.19, 27.10, 26.64, 25.32, 24.65, 24.48, 22.24 (3JCF 6.11 Hz,
2), 15.66, 12.36, 6.90, 6.13, 3.48. IR (ATR, cm1) mmax 3246,
2933, 1648, 1541, 1127, 1110, 1034. Hydrochloride salt: Mp
209–212 C. HRMS (ESI) m/z calcd 1225.7195, found 1225.7203
(M+H)+, 613.3623 (M+2H)2+.
4.1.30. Bivalent ligand 1d
The title compound was prepared following the general proce-
dure by reacting 3-aminomaraviroc 5 (56 mg, 0.1059 mmol) with
21b (73 mg, 0.1059 mmol) in 26% yield. Free base: 1H NMR
(400 MHz, DMSO-d6) d 10.00 (s, 1H), 9.03 (s, 1H), 8.27 (d,
J = 8.68 Hz, 1H), 8.21 (d, J = 8.32 Hz, 1H), 8.08 (t, J = 5.82 Hz, 1H),
8.02 (t, J = 5.72 Hz, 1H), 7.61 (s, 1H), 7.44 (d, J = 9.04 Hz, 1H), 7.27
(t, J = 7.88 Hz, 1H), 7.03 (d, J = 7.52 Hz, 1H), 6.58 (d, J = 7.88 Hz,
1H), 6.52 (d, J = 8.64 Hz, 1H), 4.93 (q, J = 7.44 Hz, 1H), 4.88 (s,
1H), 4.59 (d, J = 8.08 Hz, 1H), 4.22 (m, 1H), 4.13 (s, 2H), 4.03 (s,
2H), 3.94 (s, 2H), 3.93 (s, 2H), 3.50 (m, 1H), 3.30–3.20 (m, 2H),
3.20–3.08 (m, 6H), 3.00 (m, 1H), 2.65–2.60 (m, 3H), 2.40–2.25
(m, 10H), 2.10–1.95 (m, 3H), 1.93 (m, 1H), 1.85–1.70 (m, 7H),
1.70–1.50 (m, 7H), 1.43 (m, 7H), 1.30–1.20 (m, 12H), 0.83 (1H),
0.46 (m, 2H), 0.10 (m, 2H); 13C NMR (100 MHz, CDCl3) d 173.88,
169.11, 168.86, 168.62, 167.75, 159.16, 150.79, 143.11, 137.87,
130.68, 129.23, 122.82, 119.31, 119.19, 118.24, 118.09, 91.65,
71.63, 71.38, 70.95, 70.07, 62.34, 59.26, 58.90, 58.46, 58.33,
51.89, 50.31, 47.84, 47.25, 42.66, 38.99, 38.77, 35.14, 35.00, 32.82
(2JCF 24.4 Hz, 2), 29.31, 28.99, 28.25, 26.66, 26.28, 26.00, 25.92,
25.79, 23.53, 22.69, 21.60, 13.04, 9.26, 4.08, 3.74. IR (ATR, cm1)
mmax 3271, 3078, 2931, 2858, 2162, 2036, 1980, 1655, 1537,
1448, 1323, 1252, 1107, 1035. HRMS (ESI) m/z calcd 1197.6882,
found 599.3652 (M+2H)2+.
4.1.31. Monovalent ligand 2a
The title compound was prepared following the general proce-
dure by reacting methylcarbamoylmethoxy-acetic acid 221 (24 mg,
0.163 mmol) with 20a (86 mg, 0.158 mmol) in 30% yield. Free
base: 1H NMR (400 MHz, CD3OD) d 6.75 (m, 2H), 4.70 (d,
J = 7.68 Hz, 1H), 4.080 (s, 2H), 4.076 (s, 2H), 4.04 (s, 4H), 3.72 (m,
1H), 3.28–3.20 (m, 4H), 3.12 (m, 2H), 2.88 (m, 2H), 2.80 (m, 4H),
2.75–2.55 (m, 2H), 2.02 (m, 1H), 1.76 (d, J = 13.04 Hz, 1H), 1.70–
1.50 (m, 8H), 1.39 (m, 2H), 1.12 (m, 1H), 0.84 (m, 1H), 0.75 (m,
1H), 0.52 (m, 2H); 13C NMR (100 MHz, CD3OD) d 171.75, 143.80,
143.15, 130.75, 121.85, 121.02, 119.72, 91.89, 71.64, 71.50, 71.39,
64.40, 58.87, 52.41, 47.62, 39.97, 39.92, 31.18, 30.05, 28.94,
25.95, 25.21, 24.67, 24.55, 6.90, 6.25, 3.48. IR (ATR, cm1) mmax
3274, 2934, 1645, 1549, 1323, 1125, 1034, 857. Mp 115–118 C.
HRMS (ESI) m/z calcd 672.3603, found 672.3627 (M+H)+.
4.1.32. Monovalent ligand 2b
Previously reported.23
4.1.33. Monovalent ligand 2c
The title compound was prepared following the general proce-
dure by reacting methylcarbamoylmethoxy-acetic acid 22 (23 mg,
0.156 mmol) with 20c (91 mg, 0.152 mmol) in 25% yield. Free base:
1H NMR (400 MHz, CD3OD) d 6.65 (d, J = 8.12 Hz, 1H), 6.60 (d,
J = 8.16 Hz, 1H), 4.55 (d, J = 7.64 Hz, 1H), 4.07 (s, 2H), 4.06 (s, 2H),
4.03 (s, 4H), 3.75 (m, 1H), 3.28–3.22 (m, 4H), 3.20–3.08 (m, 2H),
2.82–2.64 (m, 5H), 2.49 (m, 2H), 2.29 (m, 2H), 1.94 (m, 1H),
1.65–1.42 (m, 8H), 1.40–1.25 (m, 10H), 0.91 (m, 1H), 0.57 (m,
2H), 0.23 (m, 2H); 13C NMR (100 MHz, CD3OD) d 172.17, 171.57,
171.51, 171.49, 143.75, 142.15, 132.06, 124.89, 120.27, 118.78,
92.73, 71.66, 71.58, 71.56, 71.53, 71.50, 71.44, 71.40, 63.89,
60.04, 60.01, 52.49, 40.11, 40.08, 31.23, 30.48, 30.44, 30.42,
30.26, 27.96, 27.92, 27.90, 25.89, 25.30, 23.74, 9.70, 4.80, 4.06. IR
(ATR, cm1) mmax 3273, 2926, 1651, 1549, 1323, 1126, 1035, 747.
Mp 112–115 C. HRMS (ESI) m/z calcd 728.4229, found 728.4217
(M+H)+.
4.1.34. Benzyl 5-(2-(2-(methylamino)-2-oxoethoxy)acetamido)
pentylcarbamate (23a)
The title compound was prepared according to the general
amide coupling procedure by reacting acid 22 (474 mg,
3.225 mmol) with amine 17a (508 mg, 2.15 mmol) in 37% yield.
1H NMR (400 MHz, CD3OD) d 7.34–7.27 (m, 5 H), 5.06 (s, 2H),
4.01 (s, 4H), 3.24 (m, 2H), 3.11 (t, J = 6.96 Hz, 2H), 2.79 (s, 3H),
1.58–1.48 (m, 4H), 1.34 (m, 2H); 13C NMR (100 MHz, CD3OD) d
172.14, 171.52, 158.94, 138.53, 129.48, 128.96, 128.76, 71.54,
71.51, 67.34, 41.69, 39.98, 30.55, 30.09, 25.90, 25.10. Mp 85–
86.5 C. IR (ATR, cm1) mmax 3308, 2936, 1655, 1250, 1124, 732,
697.
4.1.35. Benzyl (7-(2-(2-(methylamino)-2-oxoethoxy)acetamido)
heptyl)carbamate (23b)
The title compound was prepared according to the general
amide coupling procedure by reacting acid 22 (179 mg, 1.22 mmol)
with amine 17b (268 mg, 1.01 mmol) in 67% yield. 1H NMR
(400 MHz, CDCl3) d 7.40–7.28 (m, 5H), 6.57–6.35 (m, 2H), 5.09 (s,
2H), 4.80 (brs, 1H), 4.04 (s, 2H), 4.03 (s, 2H), 3.29 (q, J = 6.80 Hz,
2H), 3.18 (q, J = 6.66 Hz, 2H), 2.87 (d, J = 4.92 Hz, 3H), 1.51 (m,
4H), 1.32 (m, 6H). IR (ATR, cm1) mmax 3312, 3093, 2935, 1665,
1361, 1278, 1264, 1239, 1081, 984, 953.
4.1.36. Benzyl 9-(2-(2-(methylamino)-2-oxoethoxy)acetamido)
nonylcarbamate (23c)
The title compound was prepared according to the general
amide coupling procedure by reacting acid 22 (327 mg, 2.22 mmol)
with amine 17c (432 mg, 1.48 mmol) in 58% yield. 1H NMR
(400 MHz, CD3OD) d 7.33–7.29 (m, 5 H), 5.06 (s, 2H), 4.02 (s, 4H),
3.25–3.22 (m, 2H), 3.10 (t, J = 7.02 Hz, 2H), 2.79 (s, 3H), 1.54–1.46
(m, 4H), 1.31 (m, 10H); 13C NMR (100 MHz, CD3OD) d 172.13,
171.45, 158.92, 138.55, 129.48, 128.95, 128.76, 71.55, 71.51,
67.32, 41.88, 40.26, 40.14, 30.92, 30.54, 30.47, 30.31, 27.97,
27.80, 25.93. Mp 98–100 C. IR (ATR, cm1) mmax 3323, 2924,
2854, 2473, 1683, 1640, 1529, 1236, 1123, 722.
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4.1.37. N-(5-aminopentyl)-2-(2-(methylamino)-2-oxoethoxy)
acetamide (24a)
The title compound was prepared in a similar way as 20a. The
obtained product was used for next step without further purifica-
tion. 1H NMR (400 MHz, CD3OD) d 4.05 (s, 4H), 3.26 (t, J = 7.08 Hz,
2H), 2.79 (s, 3H), 2.72 (t, J = 7.28 Hz, 2H), 1.60–1.51 (m, 4H), 1.38
(m, 2H); 13C NMR (100 MHz, CD3OD) d 172.20, 171.64, 71.44,
71.38, 41.81, 39.88, 31.66, 30.15, 25.89, 25.06. IR (ATR, cm1) mmax
3293, 2937, 1651, 1564, 1125, 746.
4.1.38. N-(7-aminoheptyl)-2-(2-(methylamino)-2-oxoethoxy)
acetamide (24b)
The title compound was prepared in a similar way as 20a. The
obtained product was used for next step without further
purification.
4.1.39. N-(9-aminononyl)-2-(2-(methylamino)-2-oxoethoxy)
acetamide (24c)
The title compound was prepared in a similar way as 20a. The
obtained product was further recrystallized with MeOH/EtOAc to
give 74 mg white solid in 30% yield. 1H NMR (400 MHz, CD3OD) d
4.02 (s, 4H), 3.24 (t, J = 7.18 Hz, 2H), 2.79 (s, 3H), 2.77 (m, 2H),
1.54 (m, 4H), 1.34 (m, 10H); 13C NMR (100 MHz, CD3OD) d
172.15, 171.49, 71.53, 71.48, 41.53, 40.06, 30.95, 30.73, 30.43,
30.25, 30.23, 27.91, 27.64, 25.89. Mp 90–94 C. IR (ATR, cm1) mmax
3310, 2923, 2852, 1652, 1546, 1125.
4.1.40. 17-Methylamino-5,13,17-trioxo-3,15-dioxa-6,12-diaza-
heptadecan-1-oic acid (25a)
The title compound was prepared in a similar way as 18a. The
obtained product was used for next step without further purifica-
tion. 1H NMR (400 MHz, CD3OD) d 4.18 (s, 2H), 4.04 (s, 2H), 4.03 (s,
4H), 3.26 (m, 4H), 2.79 (s, 3H), 1.61–1.54 (m, 4H), 1.38 (m, 2H); 13C
NMR (100 MHz, CD3OD) d 173.77, 172.18, 171.97, 171.55, 71.59,
71.52, 71.50, 69.32, 39.95, 39.84, 30.05, 30.03, 25.91, 25.19.
4.1.41. 19-Methylamino-5,15,19-trioxo-3,17-dioxa-6,14-diaza-
nonadecan-1-oic acid (25b)
The title compound was prepared in a similar way as 18a. The
obtained product was used for next step without further purifica-
tion. 1H NMR (400 MHz, DMSO-d6) d 7.93 (m, 1H), 7.48 (t,
J = 7.52 Hz, 1H), 7.37 (t, J = 7.58 Hz, 1H), 4.20 (s, 2H), 3.94 (s, 2H),
3.91 (s, 4H), 2.65 (d, J = 4.48 Hz, 1H), 1.41 (m, 4H), 1.26 (m, 6H).
IR (ATR, cm1) mmax 3307, 3091, 2930, 2857, 2532, 1736, 1633,
1552, 1437, 1220, 1130, 1048.
4.1.42. 21-Methylamino-5,17,21-trioxo-3,19-dioxa-6,16-diaza-
henicosan-1-oic acid (25c)
The title compound was prepared in a similar way as 18a. The
obtained product was further recrystallized with MeOH/EtOAc to
give 46 mg white solid in 44% yield. 1H NMR (400 MHz, CD3OD) d
4.14 (m, 2H), 4.10 (m, 1H), 4.04–4.03 (m, 5H), 3.24 (m, 4H), 2.79
(s, 3H), 1.54 (m, 4H), 1.34 (m, 10H); 13C NMR (100 MHz, CD3OD)
d 174.27, 172.18, 171.99, 171.49, 71.50 (2), 71.47, 69.72, 40.10,
40.02, 30.48, 30.43, 30.35, 30.26 (2), 27.92, 27.89, 25.86. Mp
67–70 C. IR (ATR, cm1) mmax 3244, 2927, 1640, 1549, 1156, 681.
4.1.43. Monovalent ligand 3a
The title compound was prepared following the general proce-
dure by reacting acid 25a (40 mg, 0.0832 mmol) with 4-aminomar-
aviroc (50 mg, 0.0832 mmol) in 66% yield. Hydrochloride salt: 1H
NMR (400 MHz, CD3OD) d 7.64 (d, J = 7.84 Hz, 2H), 7.42 (d,
J = 8.00 Hz, 2H), 4.98 (m, 1H), 4.34 (m, 1H), 4.24–4.21 (m, 3H),
4.13 (s, 2H), 4.03 (s, 4H), 3.80 (m, 1H), 3.28–3.22 (m, 6H), 2.88
(m, 4H), 2.79 (s, 3H), 2.70 (m, 1H), 2.55–2.34 (m, 7H), 2.34–2.18
(m, 3H), 2.18–2.03 (m, 2H), 2.03–1.65 (m, 6H), 1.65–1.50 (m,
4H), 1.50–1.30 (m, 8H); 13C NMR (100 MHz, CD3OD) d 162.43,
154.33, 138.66, 138.43, 128.42, 122.08, 98.08, 72.01, 71.79, 71.51,
71.48, 63.43, 62.80, 56.57, 51.74, 43.50, 43.44, 39.98, 39.93,
37.38, 36.00, 34.84, 34.78, 33.96 (2JCF 24.8 Hz, 2), 31.99, 30.06,
30.02, 27.19, 27.10, 27.05, 26.75, 25.93, 25.22, 24.92, 21.62 (3JCF
3.49 Hz, 2), 15.65. IR (ATR, cm1) mmax 3270, 1644, 1549, 1402,
1126, 1108. Mp 157–159 C. HRMS (ESI)m/z calcd 858.5048, found
858.5054 (M+H)+.
4.1.44. Monovalent ligand 3b
Previously reported.23
4.1.45. Monovalent ligand 3c
The title compound was prepared following the general proce-
dure by reacting acid 25c (32 mg, 0.0799 mmol) with 4-aminomar-
aviroc (40 mg, 0.0666 mmol) in 62% yield. Hydrochloride salt: 1H
NMR (400 MHz, CD3OD) d 7.64 (d, J = 8.12 Hz, 2H), 7.42 (d,
J = 8.28 Hz, 2H), 4.98 (m, 1H), 4.34 (m, 1H), 4.24 (m, 3H), 4.15 (s,
2H), 4.061 (s, 2H), 4.058 (s, 2H), 3.79 (m, 1H), 3.27–3.22 (m, 6H),
3.17–3.11 (m, 2H), 2.88 (m, 4H), 2.80 (s, 3H), 2.45 (m, 7H), 2.28
(m, 2H), 2.09 (m, 2H), 1.92–1.74 (m, 6H), 1.55 (m, 4H), 1.44 (d,
J = 6.48 Hz, 6H), 1.33 (m, 10H); 13C NMR (100 MHz, CD3OD) d
171.76, 171.60, 170.32, 162.42, 161.77, 154.23, 138.57, 138.52,
128.41, 122.05, 71.83, 71.60, 71.34, 71.31, 63.43, 62.80, 56.57,
51.74, 50.49, 50.01, 43.49, 43.42, 40.11, 40.07, 37.36, 35.98,
34.82, 34.77, 33.83 (2JCF 24.3 Hz, 2), 31.97, 30.30, 30.08, 30.06,
27.77, 27.06, 26.74, 25.96, 24.91, 21.60 (3JCF 3.3 Hz, 2), 15.65,
12.13. IR (ATR, cm1) mmax 3244, 2943, 1647, 1540, 1407, 1132,
1110, 1038. Mp 204–207 C. HRMS (ESI)m/z calcd 914.5674, found
914.5600 (M+H)+.
4.1.46. Monovalent ligand 3d
The title compound was prepared following the general proce-
dure by reacting acid 25b (40 mg, 0.1065 mmol) with 3-amino-
maraviroc 5 (70 mg, 0.1165 mmol) in 33% yield. 1H NMR
(400 MHz, MeOD) d 7.79 (s, 1H), 7.48 (d, J = 8.04 Hz, 1H), 7.38 (t,
J = 7.86 Hz, 1H),7.23 (d, J = 7.44 Hz, 1H), 5.00 (m, 1H), 4.71 (m,
1H), 4.34 (m, 1H), 4.23 (m, 3H), 4.14 (s, 2H), 4.03 (s, 4H), 3.68
(seq, J = 6.66 Hz, 1H), 3.28–3.20 (m, 5H), 3.13 (m, 1H), 2.80 (m,
8H), 2.55–2.20 (m, 9H), 2.10 (m, 2H), 1.96 (m, 1H), 1.95–1.67 (m,
5H), 1.56 (m, 4H), 1.42 (d, J = 6.56 Hz, 6H), 1.37 (m, 6H); 13C
NMR (400 MHz, MeOD) d 171.96, 168.83, 165.97, 158.67, 139.58,
130.51, 121.41, 120.36, 71.98, 71.70, 71.43, 66.89, 63.68, 43.49,
40.07, 40.01, 36.45, 34.94, 33.87, 30.32, 29.92, 27.80, 26.70,
21.78, 21.72, 15.43. IR (ATR, cm1) mmax 3256, 3055, 2933, 2857,
2531, 2162, 1652, 1545, 1445, 1108. HRMS (ESI) m/z calcd
886.5361, found 886.5404 (M+H)+, 908.5211 (M+Na)+.
4.2. Radioligand binding assay
4.2.1. MOR radioligand binding
MOR–CHO cell culture and membrane homogenate preparation
followed the literature report.50 Saturation binding was performed
by incubating membranes for 90 min at 30 C with 0.5–15 nM [3H]
naloxone in assay buffer in a 0.5 mL volume. Non-specific binding
was determined with 5 lM naltrexone. For competition assays,
membranes were incubated as above with 2 nM [3H] naloxone
and various concentrations of unlabeled ligand, to determine com-
petitor IC50 for MOR. The reaction was terminated by rapid filtra-
tion through Whatman GF-B glass fiber filters, followed by 3
washes with 3 mL ice-cold Tris buffer. Bound radioactivity was
determined by liquid scintillation spectrophotometry at 45% effi-
ciency for [3H].
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4.2.2. CCR5 radioligand binding
The CCR5 competitive radioligand binding assay was conducted
by EMD Millipore, St. Charles, MO. Compounds were mixed 1:1
with [125I]-MIP-1a (concentrations of sample compounds were
25 lM with subsequent three-fold dilutions; fixed concentration
of [125I]-MIP-1b were 0.25 nM). The reaction was initiated by the
addition of CCR5, rhesus macaque membranes prepared in assay
buffer at (2) with a final 1 unit/well. After all sample additions,
the assay plate was allowed to incubate at room temperature in
a non-binding plate for 120 min. Prior to harvesting, the FC filter
plate was pre-coated with 0.3% PEI for 1 h. Samples were collected
and the filter plate was washed three times in wash buffer (50 mM
HEPES, pH 7.4, 500 mM NaCl, and 0.1% BSA). The filtration plate
was allowed to dry, followed by the addition of scintillation fluid
at 50 lL per well. Radiolabeled samples were measured on a Perkin
Elmer (Wallac) 1450 Microbeta TriLux liquid scintillation counter
to determine assay counts per minute.
4.3. Calcium mobilization assays
4.3.1. MOR calcium mobilization
hMOR-CHO cells4 were first transfected with Gqi5 pcDNA16
using Lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s recommended procedure. Then cells were incubated for
6 h at 37 C and 5% CO2 and then trypsinized and transferred to a
clear bottom, black 96-well plate (Greiner Bio-one) at 20,000 cells
per well in DMEM/F-12 supplemented with 5% fetal bovine serum,
100 l/mL penicillin, 100 lg/mL streptomycin, and 0.25 mg/mL
hygromycin B. Forty eight hours after transfection the growth
media was decanted and wells were washed with 100 lL of 50:1
HBSS:HEPES assay buffer. Cells were then incubated with 55 lL
of Fluo4 loading buffer [30 lL 2 lM Fluo4-AM (Invitrogen), 84 lL
2.5 mM probenacid, in 5.5 mL assay buffer] for 30 min. Varying
concentrations of ligands and controls were added to the wells to
bring the total volume up to 80 lL in each well and the plates were
subsequently incubated for 15 min. Plates were then read on a
FlexStation3 microplate reader (Molecular Devices) at 494/516
ex/em for a total of 90 s. After 15 s of reading, 20 lL of 1.25 lM
DAMGO in assay buffer, or assay buffer alone, was added to the
wells to bring the total volume up to 100 lL. The changes in Ca2
+ mobilization were monitored and peak height values were
obtained using SoftMaxPro software (Molecular Devices). Non-lin-
ear regression curves and IC50s were generated using GraphPad
Prism 3.0 (San Diego, CA). All experiments were repeated a total
of three times.
4.3.2. CCR5 calcium mobilization
CCR5-MOLT-4 cells were transfected with Gqi5 pcDNA16 using
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s
recommended procedure and maintained in RPMI 1640 supple-
mented with 10% fetal bovine serum, 100 l/mL penicillin,
100 lg/mL streptomycin, and 1 mg/mL G418 at 37 C and 5% CO2.
Forty eight hours after transfection, a total of 2,500,000 cells were
spun down and brought back up in 8 mL of 50:1 HBSS:HEPES assay
buffer. Cells were then plated at 25,000 cells per well into a clear
bottom, black 96-well plate (Greiner Bio-one) and 50 lL of Fluo4
loading buffer [40 lL 2 lM Fluo4-AM (Invitrogen), 100 lL
2.5 mM probenacid, in 5 mL assay buffer] was added to bring the
volume up to 130 lL. After incubating for 45 min, 50 lL of varying
concentrations of ligands and controls were added and the plate
was incubated for an additional 15 min. Plates were then read on
a FlexStation3 microplate reader (Molecular Devices) at 494/516
ex/em for a total of 120 s. After 16 s of reading, 20 lL of 200 nM
RANTES (Biosource) in assay buffer, or assay buffer alone, was
added to the wells to bring the total volume up to 200 lL. The
changes in Ca2+ mobilization were monitored and peak height val-
ues were obtained using SoftMaxPro software (Molecular Devices).
Non-linear regression curves and IC50s were generated using
GraphPad Prism 3.0 (San Diego, CA). All experiments were
repeated a total of three times.
4.4. Cell fusion assay
For the cell fusion assay two cell populations were constructed:
target cells containing CCR5, MOR, CD4, and pT7EMCLuc; and
effector cells containing pCAGGS-SF162gp160 and pCAGT7pol.
The established CCR5–MOR cells (target cells) were transfected
with the plasmids pcDNA3.1 CD4 (PMID: 17722977) and pT7EM-
CLuc (PMIDs: 9770428, 9349488, and 14625051) using Lipofec-
tamine 2000 (Invitrogen) according to the manufacturer’s
recommended procedure. HEK-293T (GenHunter Corporation;
Nashville, TN, USA; catalog number Q401) cells (effector cells)
were also transfected with plasmids pCAGGS-SF162gp160 (PMIDs:
10890360, 9737584, and 8995695) and pCAGT7pol using
polyethylenimine (Polysciences, Inc.; Warrington, PA, USA; catalog
number 23966). Prior to being overlaid, compound dilutions were
added to a 96-well, white, clear bottom plate at 25 lL of 5 times
concentration stock. For morphine stimulation assays, morphine
stock was added to the 5 times concentrated stocks to give a final
concentration of 500 nM in test wells. 24 h post transfection, the
target and effectors cells were detached and overlaid onto each
other at a 1:1 mixture in the 96-well white, clear bottom plate at
a final concentration of 15,000 cells/well and incubated at 37 C
and 5% CO2. After an additional 24 h, 96 well plates are allowed
to reach room temperature in darkness. Once equilibrated,
100 lL of a luciferin-lysis buffer solution was added (Bright-Glo
Luciferase Assay System, Promega). Plates were allowed to incu-
bate for 2 min and read luminescence for each well with a FlexSta-
tion3 plate reader (Molecular Devices). IC50s were obtained using
GraphPad Prism. All experiments repeated a total of three indepen-
dent times.
4.5. HIV-1 invasion assay
In a 24-well plate, primary human astroglia (ScienCell catalog
#1901) were infected by incubation with the CCR5- (R5-) tropic
HIV-1 strain SF162 obtained through the NIH AIDS Research and
Reference Reagent Program. A concentration of HIV-1 p24
50 pg/106 cells was used and uninfected cells served as a negative
control. Cells were treated with and without morphine (500 nM)
along with naltrexone (1.5 lM), maraviroc (increasing concentra-
tions of 10, 50, 100, 500 nM), and bivalent compound 1b (increas-
ing concentrations of 10, 50, 100, 500 nM) 60 min before HIV-1
infection. After approximately 18 –20 h, the supernatant was
removed and stored at 80 C, cells were rinsed twice with PBS
and lysed. The lysate was subsequently tested for the relative Tat
protein expression by using a luciferase assay system (Promega).
Luciferase activity was measured using a PHERAstar FS plate reader
(BMG Labtech).
Interactions between opioids and HIV-1 entry inhibitors in
human glial: compare maraviroc and the bivalent ligand 1. Primary
human astrocytes (HA) (ScienCell catalog # 1901) were cultured in
24-well plates and transfected with the plasmid pBlue30LTR-luc
(NIH AIDS Research and Reference Reagent Program) using Lipo-
fectamine 2000 (Invitrogen) followed by treatment with the
CCR5 antagonist, maraviroc (MVC, 100 nM), morphine (M,
500 nM), naltrexone (NTX, 1.5 lM), bivalent ligand 1 (100 nM) as
indicated and infected with HIV-1SF162 (R5) at a concentration
of HIV-1 p24 50 pg/106 cells (Fig. 5). Eighteen hours later, relative
Tat protein expression was determined by measuring luciferase
using the Luciferase Assay System (Promega) according to manu-
facturer’s protocol.
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4.6. PCR study of CCR5–hMOR CHO and astrocytes
Total RNA was isolated from the CCR5–MOR CHO cell line and
two lots of primary human astrocytes from two different individu-
als (ScienCell Research Laboratories; Carlsbad, CA, USA; catalog
number 1800) using the miRNeasy Mini Kit (Qiagen, Inc.; Valencia,
CA, USA) and used to generate cDNA templates by reverse tran-
scription using the High Capacity cDNA Reverse Transcription Kit
(Applied Biosystems; Carlsbad, CA, USA) according to the manufac-
turer’s instructions. PCR reactions were performed in a total vol-
ume of 20 lL containing SensiMix SYBR qPCR reagents (Bioline
USA, Inc.; Tauton, MA, USA) using a Corbett Rotor-Gene 6000
real-time PCR system (Qiagen, Inc.). PCR conditions consisted of
an initial hold step at 95 C for 10 min followed by 35 amplification
cycles of 95 C for 5 s, 55 C for 10 s, and 72 C for 20 s. Sequences
of the primer sets used were forward: 50-CCCAACCTCTTCCAACATT
GAGCAA-30 and reverse: 50-AACGGAGCAGTTTCTGCTTCCAGAT-30
for MOR-1; forward: 50-CTGCTCAACCTGGCCATCTCT-30 and
reverse: 50-CTTTTAAAGCAAACACAGCAT GGAC-30 for CCR5;
forward: 50-CATGGCACCGTCAAGGCTGAGAA-30 and reverse:
50-CAGTGGACTCCACGACGTACTCA-30 for human GAPDH; and
forward: 50-CTGGAGAAACCTGCCAAGTA-30 and reverse: 50-
ACCACTCTGTTGCTGTAGCC-30 for hamster GAPDH. The specificity
of the amplified products was verified by melting curve analysis
and agarose gel electrophoresis. qRT-PCR data were calculated as
relative expression levels by normalization against GAPDH mRNA
using the 2DDCt method (reference PMID: 11846609).
HIV-1 infection assay on peripheral blood mononuclear cells
(PBMCs), macrophages, and astrocytes.
PBMCs were isolated from blood (Leukopak; New York Blood
Center) by Ficoll density gradient centrifugation. Briefly, blood
was diluted with 1 phosphate-buffered saline (PBS) at a ratio of
blood:PBS (1:2). Diluted blood (30 mL), was loaded very slowly
onto 10 mL of Ficoll-containing lymphocyte separation medium
(LSMTM; MP BioMedicals), and centrifuged at 1200 rpm for 30 min
at room temperature. PBMCs from the buffy coat layer were col-
lected and washed twice with ice cold PBS, and cultured in
RPMI-1640 medium (Invitrogen) supplemented with 10% FBS
(Gibco). To obtain macrophages, PBMCs were differentiated by
treating with 100 ng/mL of macrophage-colony stimulating factor
(M-CSF; Peprotech) for 6 days. Cell culture medium was aspirated
and the adherent monocyte-derived macrophages were washed
twice with Hank’s balanced salt solution (Gibco) to provide macro-
phages for subsequent experiments. Human astrocytes were
obtained from and cultured as recommended by ScienCell
Research Laboratories.
PBMCs, macrophages, and astrocytes were plated at 1  105
cells/mL in their respective types of cell culture medium, and stim-
ulated with interleukin-2 (IL-2; 100 ng/mL; Sigma–Aldrich) and
phytohaemagglutinin (PHA; 5 lg/mL; Sigma–Aldrich) for 48 h.
Stimulated cells were treated with polybrene (2 lg/mL; Sigma–
Aldrich) for 30 min and re-suspended in fresh medium. Cells were
treated with maraviroc (500 nM; Sigma–Aldrich), or bivalent com-
pounds (1b, 1c, and 1a) at 10, 100, and 1000 nM concentrations, for
1 h prior to infection with HIVBal (HIV-p24 = 1000 pg/mL;
Advanced Biotechnologies Inc., Columbia, MD) an R5-tropic HIV-
1 strain.
4.7. Cell supernatant and lysate protein collections and HIV-p24
quantifications
At 5 days post-infection, cell culture supernatants were col-
lected and cell debris was removed by spinning at 1200 rpm for
5 min. Cells were lysed using radioimmunoprecipitation assay buf-
fer (RIPA buffer; Sigma–Aldrich) supplemented with protease and
phosphatase inhibitors (Roche Applied Sciences), and cell lysate
proteins were collected by spinning at 14,000 rpm for 15 min at
4 C. Cell culture supernatants and cell lysate proteins were stored
at 80 C. Cell supernatant and lysate samples were quantified for
HIV-p24 levels using ELISA (HIV-1 p24 Antigen Capture Assay;
Advanced Bioscience Laboratories).
4.8. Dynamics simulation studies
All ligands used in the docking studies were built with standard
bond lengths and angles using the molecular modeling package
SYBYL-X 2.0. The small molecules were assigned Gasteiger-Hückel
charges and energy minimized with the Tripos Force Field.
All molecular modeling was collected using the SYBYL-X 2.0
molecular modeling package (Tripos LP, St. Louis, MO) on dual-core
AMD Opteron(tm) 2.4 GHz processors. The amino acid sequence of
chemokine receptor CCR5 was obtained from UniProtKB/Swiss-
Prot (P51681). Within ClustalX a multiple alignment was per-
formed with a gap opening penalty of 15 using the BLOSUM pro-
tein weight matrix series.47,59 Sequence alignment between CCR5
and CXCR4 was further optimized based on the most conserved
residues among most GPCRs and used for model construction for
both the inactive and active models. The comparative modeling
software, MODELLER 9v8, was used to generate 100 homology
models for each state using the default parameters.60
Model screening was performed by using the genetic-algorithm
docking program GOLD 5.1 (Cambridge Crystallographic Data Cen-
tre, Cambridge, UK) to dock maraviroc into the CCR5 homology
models using GOLD score as the fitness function.53 One receptor
model was chosen based upon the discrete optimized protein
energy (DOPE) scores, fitness function values, and the electronic
and steric interactions between the ligands and receptor. Further
model refinement was done using molecular mechanics based
energy minimization in Sybyl-X 2.0. Briefly, the model was mini-
mized using a Tripos Force Field with Gasteiger-Hückel charges,
a non-bonded interaction cutoff of 8 Å with a distance-dependent
dielectric constant of e = 4 being terminated at 0.05 kcal/(mol Å).
The minimized models were then analyzed using PROCHECK and
ProTable within SYBYL-X 2.0 to ensure the overall quality of the
models (i.e., acceptable torsion angles, steric clashes, bond lengths,
etc.).
The heterodimer was built within SYBYL-X 2.0 using the above
described CCR5 homology model and the mu opioid receptor crys-
tal structure functional dimer (PDB code: 4DKL).48 MOR was crys-
tallized as both a dimer and both a TM5/TM6 and a TM1/TM2
dimer interface were observed.47 The TM5/TM6 has more exten-
sive packing and network of interactions which make it a more
plausible dimer interface. In order to construct the heterodimer,
one of the MOR units was aligned with the CCR5 homology model
according to their homology levels. The subsequent MOR was
removed and a MOR–CCR5 heterodimer was left. Initial heterodi-
mer refinement was done using molecular mechanics based energy
minimization in Sybyl-X 2.0. Briefly, the model was minimized
using a MMFF94 force field with Gasteiger-Hückel charges, a
non-bonded interaction cutoff of 8 Å with a distance-dependent
dielectric constant of e = 4 being terminated at 0.05 kcal/(mol Å).
The minimized heterodimer was then analyzed using PROCHECK
and ProTable within SYBYL-X 2.0 to ensure the overall quality of
the models (i.e., acceptable torsion angles, steric clashes, bond
lengths, etc.).
The heterodimer interface had extensive hydrophobic and polar
interactions similar to the ones seen in the MOR homodimer.48
Using APBS, the electrostatic interfaces between MOR and CCR5
were mapped.61,62
The optimized heterodimer model was then subjected to
another round of docking of the antagonists. Using GOLD 5.1
the ligands were docked into both binding pockets of the hetero-
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dimer. The putative binding area was restricted to a 15 Å radius
around E283 and maraviroc was docked into the receptor a total
of 100 iterations using the generic GOLD docking parameters.57,58
Concurrently, naltrexone was aligned/overlapped with the mor-
phanin antagonist b-FNA within the MOR binding pocket of the
heterodimer model. The attachment site of the linker to naltrex-
one allows for the linker to span into the CCR5 binding pocket
through the TM5/TM6 interface. Therefore, of the 100 docked
poses of maraviroc, the poses with the linker portion pointed
towards the TM5/TM6 interface were sorted out for further anal-
ysis. The pose with the highest GOLD score and that was within
the proper 21-atom distance to naltrexone (linker length: 21
atoms long) was chosen. Once both the naltrexone and maravi-
roc modes were chosen, they were connected to each other using
SYBYL X 2.0 with the 21-atom linker to yield compound 1b. The
subsequent bivalent compound was then merged with the het-
erodimer and the whole system was energy minimized using a
MMFF94 force field.
All molecular dynamics simulations were run using the Teal
cluster housed at the Virginia Commonwealth University Center
for High Performance Computing. The cluster consists of 2480
64 bit AMD computer cores, each with 2–4 GB RAM/core.
The heterodimer-1b complex was further analyzed using
molecular dynamics with the CHARMM force field using nanoscale
molecular dynamics, NAMD.54,63,64 Using the program VMD (Visual
Molecular Dynamics), a solvated 150 Å  150 Å phosphatidyl-
choline (POPC) was constructed on the x–y plane.65 The CCR5–
MOR bound 1b complex was then properly orientated for insertion
into the lipid bilayer using the orientations of proteins in mem-
branes (OPM) database.66 After inserting the protein into the mid-
dle of the membrane, lipids within 0.8 Å of the protein were
removed. Next the system was solvated with TIP3 water and equi-
librated with 0.15 M NaCl ions. In the completed system there
were a total of 162,385 atoms. A modified CHARMM27 force field
was constructed with the parameters for compound 1b; the online
server SwissParam was used to calculate the CHARMM force field
for the ligand.67
Using NAMD, the system was equilibrated in a three-step pro-
cess. First, 500 ps of molecular dynamic simulation was run (with
a time step of 2 fs) on only the lipid tails of the POPC bilayer while
keeping the protein, water, ions, ligand, and lipid-head groups
fixed. During the second round of equilibration, the protein and
ligand were harmonically constrained while the rest of the system
was allowed to move. The simulation was run for 500 ps (2 fs time
step) while keeping water out of the lipid bilayer. The third step
was run completely without constraints for 500 ps while keeping
a constant area for the water box.
Molecular dynamics stimulation was then run on the equili-
brated system for 10 ns with a time step of 2 fs with the area of
the membrane kept constant. Langevin dynamics helped main-
tained a constant temperature of 310 K and a hybrid Nosé-Hoover
Langevin piston method was used to keep a constant pressure of
1 atm with an oscillation period of 200 fs. Electrostatics were
maintained using periodic boundary conditions and the particle
mesh ewalds method. A 12 Å non-bonded cutoff and a grid spacing
of 1 Å per point in each dimension while calculating van der Waals
energies using a switching radius of 10 Å and a cutoff radius of
12 Å. Trajectory analyses were carried out using VMD focusing
on the heterodimer and 1b interactions.
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